University of Central Florida

STARS
UCF Patents

Technology Transfer

2-15-2011

Tissue substitutes comprising stem cells and reduced ceria
Kiminobu Sugaya
Petya Georgieva
University of Central Florida

Stephanie Merchant
University of Central Florida

Sudipta Seal
University of Central Florida

Manny Vrotsos
University of Central Florida

Find similar works at: https://stars.library.ucf.edu/patents
University of Central Florida Libraries http://library.ucf.edu
This Patent is brought to you for free and open access by the Technology Transfer at STARS. It has been accepted for
inclusion in UCF Patents by an authorized administrator of STARS. For more information, please contact
STARS@ucf.edu.

Recommended Citation
Sugaya, Kiminobu; Georgieva, Petya; Merchant, Stephanie; Seal, Sudipta; and Vrotsos, Manny, "Tissue
substitutes comprising stem cells and reduced ceria" (2011). UCF Patents. 783.
https://stars.library.ucf.edu/patents/783

Illlll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111
US007888119B2

c12)

United States Patent

(10)

Sugaya et al.

(45)

(54)

TISSUE SUBSTITUTES COMPRISING STEM
CELLS AND REDUCED CERIA

(75)

Inventors: Kiminobu Sugaya, Winter Park, FL
(US); Stephanie Merchant, Sanford, FL
(US); Sudipta Seal, Oviedo, FL (US);
Petya Georgieva, Williamsville, NY
(US); Manny Vrotsos, Orlando, FL (US)

(73)

Assignee: University of Central Florida Research
Foundation, Inc., Orlando, FL (US)

( *)

Notice:

Subject to any disclaimer, the term ofthis
patent is extended or adjusted under 35
U.S.C. 154(b) by 77 days.

(58)

Patent No.:
US 7,888,119 B2
Date of Patent:
Feb.15,2011

Field of Classification Search ................. 435/395,
435/325; 424/93 .1, 1.29
See application file for complete search history.
References Cited

(56)

U.S. PATENT DOCUMENTS
7,141,227
7,270,813
2003/0050709
2003/0100948
2005/0159820
2005/0164377

B2 * 1112006 Chan .......................... 423/263
B2 * 9/2007 Shimp et al. ............... 424/93.7
Al
3/2003 Noth et al.
Al
5/2003 Goulet et al.
Al
7/2005 Yoshikawa et al.
Al
7/2005 Miyabayashi et al.

OTHER PUBLICATIONS

(21)

Appl. No.: 11/582,057

Ohgushi et al. J. Biomed. Mat. Res. 48:913-927; 1999.*
Maschio et al. J. Mat. Sci. 27:5591-5596; 1992.*
Ramsfjell et al. Blood 99:4093-41.2; 1999.*
Devasenpathi et al. Mat. Let. 57:882-886; 2002.*

(22)

Filed:

* cited by examiner

(65)

Oct. 16, 2006
Prior Publication Data

US 2007/0123996Al

May 31, 2007

Related U.S. Application Data
(60)

Provisional application No. 60/727,075, filed on Oct.
14, 2005.

(51)

Int. Cl.
C12N 5100
(2006.01)
AOJN 63100
(2006.01)
A61K 51100
(2006.01)
U.S. Cl. ...................... 435/395; 435/325; 424/93.1;
424/1.29

(52)

Primary Examiner-Fereydoun G Sajjadi
(74) Attorney, Agent, or Firm-Timothy H. Van Dyke;
Beusse Wolter Sanks Mora & Maire
(57)

ABSTRACT

A biocompatible composite includes a solid biocompatible
material and a plurality of living human progenitor or living
stem cells attached thereto. The biocomposite provides a
stable interface with endogenous tissue and the implanted
composition resulting in accelerated repair to damaged bones
and tissues.
14 Claims, 2 Drawing Sheets
(1 of 2 Drawing Sheet(s) Filed in Color)
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TISSUE SUBSTITUTES COMPRISING STEM
CELLS AND REDUCED CERIA

material comprises cerium oxide (ceria) stabilized zirconia.
Ceria preferably comprises at least about 10 weight% of the
bicompatible material, and is preferably more than 15 wt%,
such as 20 wt %.
In another preferred embodiment, a biocomposite, comprises a biocompatible solid material, and a plurality ofliving
human progenitor or living stem cells attached to a surface of
said biocompatible material. In one aspect the biocompatible
material is a porous material. In another aspect, the biocompatible material is solid providing a surface framework for
cells to adhere and reconstitute the damaged tissue or organ.
Ceria provides unique oxidation state transformations and
when plasma processing described herein is utilized for formation including non-equilibrium tetragonal phase formation. In a preferred embodiment, the biocompatible material
comprises a reduced state of ceria molecules on surfaces of
said material. Preferably, the surface of the biocompatible
material comprises from about 10% to about 99% Ce 3 + molecules versus Ce4 + molecules. Preferably, the surface of the
biocompatible material comprises at least about 10% Ce 3 +
molecules versus Ce4 + molecules; more preferably, the biocompatible material comprises about 20% Ce3 + molecules
versus Ce4 + molecules; more preferably, the surface of the
biocompatible material comprises about 30% Ce3 +molecules
versus Ce4 + molecules.
In another preferred embodiment, the surface of the biocompatible material comprises from about 10% to about 99%
Ce4 + molecules versus Ce3 + molecules.
In another preferred embodiment, a method of repairing
bone, comprises the steps of: obtaining live stem cells from a
patient to be treated or a haplotype matched donor; culturing
said stem cells with a biocompatible solid material, wherein
said stem cells attach to a surface of said biocompatible
material to form a biocomposite, and, positioning said biocomposite in proximity to bone to be treated, wherein said
live stem cell provides an interface between said biocompatible material and said bone, wherein said biocomposite accelerates healing of said bone.
In one embodiment, the biocompatible material is a porous
material. In an alternative embodiment, the biocompatible
material is solid material (little or no pores, or pores that are
smaller than the size ofa cell). Preferably, the biocompatible
material comprises ceria stabilized zirconia. By modifying
the process parameters, controlled porosity on the surface of
the biocompatible material, acts as scaffolding.
In a preferred embodiment, the biocompatible material
comprises a plurality of stem cell coated cores, further comprising the step of placing said plurality of coated cores inside
of said bone.
In another preferred embodiment, the biocompatible material is cultured with stem cells derived from autologous bone
marrow. The stems cells are preferably, Lin-, or Sca-1+, or
c-kit+, and/or Lin-sca-1 + c-kit+.
In another preferred embodiment, the stem cells are transduced with a vector expressing a desired molecule, such as
growth factors, stem cell targeting antigens, and the like.
Preferably, the expressed molecules, include, but are not limited to: bonemorphogenicprotein such as, OP-1, OP-2, OP-3,
COP-1, COP-3, COP-4, COP-5, COP-7, COP-16, BMP-2,
BMP-3, BMP-3b, MP-4, BMP-5, BMP-6, BMP-9, BMP-10,
BMP-11, BMP-12, BMP-13, BMP-14, B-15, BMP-16,
BMP-17, BMP-18, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6,
GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, GDF-12,
MP121, dorsalin-1, DPP, Vg-1, Vgr-1, 6Aprotein, NODAL,
UNIVIN, SCREW, ADMP, NEURAL, TGF-~ and conservative amino acid sequence variants thereof having osteogenic
activity. Other examples of useful molecules include, but are

CROSS-REFERENCE TO RELATED
APPLICATIONS
The present application claims the priority of U.S. provisional patent application Ser. No. 60/727,075 and entitled
"STEM CELL COMPRISING TISSUE SUBSTITUTES"
filed Oct. 14, 2005 which is herein incorporated by reference
in its entirety.
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STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT
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The United States Government has certain rights in this
invention pursuant to Office of Naval Research Young Investigator Award (ONR-YIP) grant no. ONR N000140210591,
Defense University Research Instrumentation Program
(DURIP) grant no. ONR N000140310858 andNeuroreplacement strategies by mesenchymal stem cell (1 ROI AG 2347201) from NIH.
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FIELD OF THE INVENTION
25

The invention relates to the field of tissue engineering,
production of connective tissue, such as tissue linked to natural bones or synthetic bone substitutes.
DESCRIPTION OF RELATED ART
Researchers in the surgical arts have been working for
many years to develop new techniques and materials for use
as grafts to replace or repair damaged or torn tissue structures,
particularly bones and connective tissues, such as ligaments
and tendons, and to hasten soft tissue repair. It is very common today for an orthopedic surgeon to harvest a central
portion of patellar tendon of autogenous or allogenous origin
for use as a replacement for a tom cruciate ligament. The
surgical methods for such approaches are well known. Further it has become common for surgeons to use implantable
prostheses formed from plastic, metal and/or ceramic material for reconstruction or replacement of physiological structures. Yet despite their wide use, surgically implanted prostheses present many attendant risks to the patient. Surgeons
are in need of a non-immunogenic, high tensile strength graft
material which can be used for surgical repair of bones, tendons, ligaments and other functional tissue structures.
Composites including partially stabilized zirconia, bioactive glass or glass-ceramics polyethylene-hydroxyapatite
have been disclosed forthe repair, reconstruction and replacement of diseased or damaged parts of the body, including
bone. However, a stable interface with connective tissue has
prevented clinical use of such biomaterials.
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SUMMARY
A biocomposite comprises biocompatible material having
plurality of living human progenitor or living stem cells
attached to a surface thereof. The human progenitor or living
stem cells provides a stable interface with endogenous tissue
(e.g. bone) that has before the invention prevented clinical use
of such biomaterials.
In a preferred embodiment, the biocompatible material is a
porous material. Preferably, the porous or non-porous biocompatible material comprises a rare earth stabilized zirconia. In a most preferred embodiment, the biocompatible
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not limited to: SCG 1O; Na Channel II; glut-2, synapsin, epo,
SCF, shh, wint, BMPs Ephrins, Pax-6, Emx-2, Mash-1,
jagged 1 and 2, notch- and 2, ephrin B2 and ephrin B4, Bmi-1,
different homeobox genes HOXB4, Factor VIII, Factor IX, or
mutant genes for ~-glucocerebrosidase, erythropoietin
("EPO"), a-L-iduronidase, iduronate sulphatase, N-sulphatase, N-acetyl a-D-glucosaminidase, a-glucosamine-Nacetyltransferase,
N-acetyl-a-D-glucosaminide-6-sulphatase,
Galactosamine-6
sulphate
sulphatase,
~-galactosidase, N-acetyl-alactosamine-4-sulphatase, acid
ceraminidase, acid sphingomyelinase, galactocerebroside
~-galactosidase, arylsuphataseA, adenosine deaminase, a-Lfucosidase growth factors such as the interleukin family,
angiogenesis stimulating or inhibiting factors such as the
nitric oxide synthases (NOSl-3), vascular endothelial growth
factors ("VEGF"), Angiostatin 1-7. Other examples of genes
useful for introduction into isolated stem cells include those
that encode von Willebrand factor, insulin, tissue plasminogen activator, any of the interleukins, or a growth factor. Some
examples of interleukins include IL-1, -2, -3, -4, -5, -6, -7, -8,
-9, -10, -11, -12, -13, -14, -15, -16, -17, -18, -19, -20, and-21.
Some examples of suitable growth factors include erythropoietin, thrombopoietin, PDGF, G-CSF, GM-CSF, IGF,
TGF~, VEGF, LIF, CNTF, FGF, EGF and BMP (bone morphogenic protein).
In yet another embodiment of the invention, a method of
repairing bone comprises the steps of obtaining live stem cells
from a patient to be treated or a haplotype matched donor,
culturing the stem cells with a biocompatible material,
wherein the stem cells attach to a surface of the biocompatible
material to form a biocomposite, and positioning the biocomposite in proximity to bone to be treated, wherein the stem cell
provides an interface between the biocompatible material and
the bone and differentiate to accelerate healing of the bone.
The biocompatible material has been found to facilitate
attachment of stem cells to surfaces of the material.
In another preferred embodiment, the biocompatible material is coated or treated with cell adhesion molecules.
Examples of cell adhesive proteins, protein fragments, or
peptides, include, but not limited to fibronectin, laminin, collagen, vitronectin, osteopontin, RGD peptides, RGDS peptides, YIGSRpeptides, ICAM-1, PECAM-1, LFA-3, LFA-1,
VLA-4, VLA-5, L-Selectin and HCAM. Bone tissue-specific
collagen (e.g., Type I collagen) derived from a number of
sources are also suitable, including soluble collagen, acidsoluble collagen, collagen soluble in neutral or basic aqueous
solutions, as well as those collagens which are commercially
available. In addition, Type II collagen, as found in cartilage,
also may be used in combination with Type I collagen.
The present invention therefore provides therapeutic,
structural, or cosmetic implants comprising the biocompatible material and at least one cell. Preferably, the at least one
cell is a bone-forming or bone-degrading cell. Particularly
useful cell types include chondrocytes, osteocytes, osteoblasts, osteoclasts, mesenchymal stem cells, fibroblasts,
muscle cells, hepatocytes, parenchymal cells, cells of intestinal origin, nerve cells, and skin cells, and may be provided
as primary tissue explants, preparations of primary tissue
explants, isolated cells, cell lines, transformed cell lines, and
host cells. The implants may also comprise additional components such as biologically active agents or factors that alter
the characteristics (such as resorbability, strength, adherence,
injectability, frictional characteristics, etc.).
The invention also provides methods of preparing such
implants; methods of growing bone or cartilage in vivo or in
vitro, at natural sites or ectopic sites; methods of osseous
augmentation; and methods of diagnosing disease states by

assaying tissue-forming potential of cells isolated from a
host. Other aspects of the invention are described infra.
BRIEF DESCRIPTION OF THE DRAWINGS

10

15

20

The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
in publication with the color drawing(s) will be provided by
the Office upon request and payment of the necessary fee. The
invention is pointed out with particularity in the appended
claims. The above and further advantages of this invention
may be better understood by referring to the following
description taken in conjunction with the accompanying
drawings, in which:
FIG. 1 shows a scanned image of mesenchymal stem cells
isolated from adult human bone marrow cultured on synthetic
bone according to the invention after staining with green
fluorescent dye.
FIG. 2 shows a scanned image of a porous, near-net shape
ceria-stabilized zirconia article for a specific bio-medical
application formed using a plasma spraying process according to the invention.
DETAILED DESCRIPTION
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A biocomposite comprises a biocompatible solid material,
and a plurality ofliving human progenitor or living stem cells
attached to a surface of the biocompatible material. The stem
cells on the surface of the biocomposite provides a stable
interface with connective tissue which has been an unsolved
issue for clinical use of biomaterials. The biocompatible
material can be a macro scale article, or comprise a plurality of
microscale or nanoscale core particles. The biocompatible
material is preferably a porous material.
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The present section provides definitions of the terms used
in the present invention in order to facilitate a better understanding of the invention.
As used herein, the singular forms "a", "an" and "the"
include plural referents unless the context clearly dictates
otherwise.
A "stem cell" is a relatively undifferentiated cell that can be
induced to proliferate and that can produce progeny that
subsequently differentiate into one or more mature cell types,
while also retaining one or more cells with parental developmental potential. In many biological instances, stem cells are
also "multi potent" because they can produce progeny of more
than one distinct cell type, but this is not required for "sternness." Self-renewal is the other classical part of the stem cell
definition, and it is essential as used in this document. In
theory, self-renewal can occur by either of two major mechanisms. Stem cells may divide asymmetrically, with one
daughter retaining the stem state and the other daughter
expressing some distinct other specific function and phenotype. Alternatively, some of the stem cells in a population can
divide symmetrically into two stems, thus maintaining some
stem cells in the population as a whole, while other cells in the
population give rise to differentiated progeny only. Formally,
it is possible that cells that begin as stem cells might proceed
toward a differentiated phenotype, but then "reverse" and
re-express the stem cell phenotype.
"Progenitor cells" have a cellular phenotype that is more
primitive (i.e., is at an earlier step along a developmental
pathway or progression than is a fully differentiated cell).
Often, progenitor cells also have significant or very high
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proliferative potential. Progenitor cells may give rise to multiple distinct differentiated cell types or to a single differentiated cell type, depending on the developmental pathway and
on the environment in which the cells develop and differentiate. Like stem cells, it is possible that cells that begin as
progenitor cells might proceed toward a differentiated phenotype, but then "reverse" and re-express the progenitor cell
phenotype.
"Differentiation" refers to the developmental process
whereby cells assume a specialized phenotype, i.e., acquire
one or more characteristics or functions distinct from other
cell types. In most uses, the differentiated phenotype refers to
a cell phenotype that is at the mature endpoint in some developmental pathway. In many but not all tissues, the process of
differentiation is coupled with exit from the cell cycle-in
these cases, the cells lose or greatly restrict their capacity to
proliferate when they differentiate.
"Osteoinduction" refers to stimulating bone growth at a
site within a subject at which little or no bone growth would
occur ifthe site were left untreated. Sites which could therapeutically benefit from the induction of bone growth are
referred to as "in need of osteoinduction". Examples include
non-union fractures or other severe or massive bone trauma. It
is noted that bone growth normally occurs at bone injuries
such as simple or hairline fractures and well opposed complex
fractures with minimal gaps without the need for further
treatment. Such injuries are not considered to be "in need of
osteoinduction". Simple fracture repair appears to be quite
different from the induction of bone formation required to fill
non-union fractures, segmental gaps or bone voids caused, for
example, by removal of a bone tumor or cyst. These cases
require bone grafting or induction of new bone growth generally employing some type of matrix or scaffolding to serve
as a bone growth substitute. Induced bone growth can also be
therapeutically beneficial at certain sites within a subject
(referred to as "ectopic" sites) where bone tissue would not
normally be found, such as a site in need of a bone graft or
bone fusion. Fusions are commonly used to treat lower back
pain by physically coupling one or more vertebrae to its
neighbor. The bone created by such a fusion is located at a site
not normally occupied by bone tissue. Osteoinduction at
these ectopic sites can act as a "graft substitute" whereby
induced bone growth between the vertebrae takes the place of
a graft and obviates the need for a second operation to harvest
bone for the grafting procedure. Induction of bone growth is
also needed for treating acquired and congenital craniofacial
and other skeletal or dental anomalies (see e.g., Glowacki et
al., Lancet 1: 959 (1981)); performing dental and periodontal
reconstructions where lost bone replacement or bone augmentation is required such as in a jaw bone; and supplementing alveolar bone loss resulting from periodontal disease to
delay or prevent tooth loss (see e.g., Sigurdsson et al., J.
Periodontal., 66: 511 (1995)).
"Amorphous"-By "amorphous" as that term is used here,
it is meant a material with significant amorphous character.
Significant amorphous character contemplates greater than
75% amorphous content, preferably greaterthan 90% amorphous content, and is characterized by a broad, featureless
X-ray diffraction pattern. It is recognized that a small degree
of crystallinity may exist in such material.
"Bioactive"-"Bioactive" refers to a material that induces
hard tissue formation in and about the implant. When
implanted in soft tissue, the bioactivity may also require the
presence of a growth or trophic factor, or the seeding of the
implant with a hard tissue forming cell type.
"Biocompatible"-The term "biocompatible", as used
herein, means that the material does not elicit a substantial

detrimental response in the host. There is always concern,
when a foreign object is introduced into a living body, that the
object will induce an immune reaction, such as an inflammatory response that will have negative effects on the host. For
example, although hydroxyapatite is generally considered to
be "biocompatible", significant inflanimation and tissue
necrosis have been observed when crystalline hydroxyapatite
microcarriers are inserted intramuscularly in animals (see, for
example, IJntema et al., Int. J. Pharm 112:215, 1994).
"Bioresorbable"-"Bioresorbable" or "resorbable" refers
to the ability of a material to be resorbed in vivo. "Full"
resorption means that no significant extracellular fragments
remain. The resorption process involves elimination of the
original implant materials through the action of body fluids,
enzymes or cells. Resorbed calcium phosphate may, for
example, be redeposited as bone mineral, or by being otherwise reutilized within the body, or excreted. "Strongly bioresorbable", as that term is used herein, means that at least 80%
of the total mass of material implanted intramuscularly or
subcutaneously is resorbed within one year.
"Cells"-the term "cells", as used herein, refers to any
preparation ofliving tissue, including primary tissue explants
and preparations thereof, isolated cells, cells lines (including
transformed cells), and host cells.
"Effective Amount"-An effective amount of a biologically active agent is an amount sufficient to elicit a desired
biological response.
"Biodegradable agent" refers to a resorbable biocompatible material such as a material that degrades gradually at the
implant site. The material is capable of encapsulating a bioactive agent to provide time release or sustained release delivery of the bioactive agent. The biodegradable material
encompasses natural and synthetic polymers. Examples of
biodegradable material are poly(L-lactide) (PLLA), poly(D,
L-lactide) (PDLLA), polyglycolide (PGA), poly(lactide-coglycolide (PLGA) and co-polymers thereof.
"Bone" refers to a calcified (mineralized) connective tissue
primarily comprising a composite of deposited calcium and
phosphate in the form ofhydroxyapatite, collagen (primarily
Type I collagen) and bone cells such as osteoblasts, osteocytes and osteoclasts, as well as to bone marrow tissue which
forms in the interior of true endochondral bone. Bone tissue
differs significantly from other tissues, including cartilage
tissue. Specifically, bone tissue is vascularized tissue composed of cells and a biphasic medium comprising a mineralized, inorganic component (primarily hydroxyapatite crystals) and an organic component (primarily of Type I
collagen). Glycosaminoglycans constitute less than 2% of
this organic component and less than 1% of the biphasic
medium itself, or of bone tissue per se. Moreover, relative to
cartilage tissue, the collagen present in bone tissue exists in a
highly-organized parallel arrangement. Bony defects,
whether from degenerative, traumatic or cancerous etiologies, pose a formidable challenge to the reconstructive surgeon. Particularly difficult is reconstruction or repair of skeletal parts that comprise part of a multi-tissue complex, such as
occurs in manimalianjoints.
"Bone formation" means formation of endochondral bone
or formation of intramembranous bone. In humans, bone
formation begins during the first 6-8 weeks of fetal development. Progenitor stem cells of mesenchymal origin migrate to
predetermined sites, where they either: (a) condense, proliferate, and differentiate into bone-forming cells (osteoblasts ),
a process observed in the skull and referred to as "intramembranous bone formation" or, (b) condense, proliferate and
differentiate into cartilage-forming cells (chondro blasts) as
intermediates, which are subsequently replaced with bone-
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forming cells. More specifically, mesenchymal stem cells
differentiate into chondrocytes. The chondrocytes then
become calcified, undergo hypertrophy and are replaced by
newly formed bone made by differentiated osteoblasts, which
now are present at the site. Subsequently, the mineralized
bone is extensively remodeled, thereafter becoming occupied
by an ossicle filled with functional bone-marrow elements.
This process is observed in long bones and referred to as
"endochondral bone formation." In postfetal life, bone has the
capacity to repair itself upon injury by mimicking the cellular
process of embryonic endochondral bone development. That
is, mesenchymal progenitor stem cells from the bone-marrow, periosteum, and muscle can be induced to migrate to the
defect site and begin the cascade of events described above.
There, they accumulate, proliferate, and differentiate into
cartilage, which is subsequently replaced with newly formed
bone.
"Bone morphogenic protein (BMP)" refers to a protein
belonging to the BMP family of the TGF-~ superfamily of
proteins (BMP family) based on DNA and amino acid
sequence homology. A protein belongs to the BMP family
according to this invention when it has at least 50% amino
acid sequence identity with at least one known BMP family
member within the conserved C-terminal cysteine-rich
domain which characterizes the BMP protein family. Members of the BMP family may have less than 50% DNA or
amino acid sequence identity overall.
"Conservative substitutions" are residues that are physically or functionally similar to the corresponding reference
residues. That is, a conservative substitution and its reference
residue have similar size, shape, electric charge, chemical
properties including the ability to form covalent or hydrogen
bonds, or the like. Examples of conservative substitutions are
substitutions within the following groups: (a) valine, glycine;
(b) glycine, alanine; (c) valine, isoleucine, leucine; (d) aspartic acid, glutamic acid; (e) asparagine, glutamine; (f) serine,
threonine; (g) lysine, arginine, methionine; and (h) phenylalanine, tyrosine. The term "conservative variant" or "conservative variation" also includes the use of a substituting amino
acid residue in place ofan amino acid residue in a given parent
amino acid sequence, where antibodies specific for the parent
sequence are also specific for, i.e., "cross-react" or "immunoreact" with, the resulting substituted polypeptide sequence.
"Defect" or "defect site" refers to a site requiring bone,
joint, cartilage or ligament repair, construction, fusion, regeneration or augmentation. The site may be an orthopedic structural disruption or abnormality, or a site where bone does not
normally grow. The defect further can define an osteochondral defect, including a structural disruption of both the bone
and overlying cartilage. A defect can assume the configuration of a "void", which is understood to mean a three-dimensional defect such as, for example, a gap, cavity, hole or other
substantial disruption in the structural integrity of a bone or
joint. A defect can be the result of accident, disease, surgical
manipulation, and/or prosthetic failure. In certain embodiments, the defect is a void having a volume incapable of
endogenous or spontaneous repair. Such defects in long bone
are generally twice the diameter of the subject bone and are
also called "critical size" defects. For example, in a canine
ulna defect model, the art recognizes such defects to be
approximately 3-4 cm. Generally, critical size defects are
approximately 1.0 cm, and incapable of spontaneous repair.
See, for example, Schmitz et al., Clinical Orthopaedics and
Related Research, 205, pp. 299-308 (1986); and Vukicevic et
al., in Advances in Molecular and Cell Biology, 6, pp. 207224 (1993)(JAI Press, Inc.). In rabbit and monkey segmental
defect models, the gap is approximately 1.5 cm and 2.0 cm,

respectively. In other embodiments, the defect is a non-critical size segmental defect. Generally, these are capable of
spontaneous repair. In certain other embodiments, the defect
is an osteochondral defect, such as an osteochondral plug.
Such a defect traverses the entirety of the overlying cartilage
and enters, at least in part, the underlying bony structure. In
contrast, a chondral or subchondral defect traverses the overlying cartilage, in part or in whole, respectively, but does not
involve the underlying bone. Other defects susceptible to
repair using the instant invention include, but are not limited
to, non-union fractures; bone cavities; tumor resection; fresh
fractures (distracted or undistracted); cranial, maxillofacial
and facial abnormalities, for example, in facial skeletal reconstruction, specifically, orbital floor reconstruction, augmentation of the alveolar ridge or sinus, periodontal defects and
tooth extraction socket; cranioplasty, genioplasty, chin augmentation, palate reconstruction, and other large bony reconstructions; vertebroplasty, interbody fusions in the cervical,
thoracic and lumbar spine and posteriolateral fusions in the
thoracic and lumbar spine; in osteomyelitis for bone regeneration; appendicular fusion, ankle fusion, total hip, knee and
joint fusions or arthroplasty; correcting tendon and/or ligamentous tissue defects such as, for example, the anterior,
posterior, lateral and medial ligaments of the knee, the patella
and achilles tendons, and the like as well as those defects
resulting from diseases such as cancer, arthritis, including
osteoarthritis, and other bone degenerative disorders such as
osteochondritis dessicans.
"Morphogenic protein" refers to a protein having morphogenie activity (see below). Preferably a morphogenic protein
of this invention comprises at least one polypeptide belonging
to the BMP protein family. Morphogenic proteins may be
capable of inducing progenitor cells to proliferate and/or to
initiate differentiation pathways that lead to cartilage, bone,
tendon, ligament, neural or other types of tissue formation
depending on local environmental cues, and thus morphogenic proteins may behave differently in different surroundings. For example, an osteogenic protein may induce bone
tissue at one treatment site and neural tissue at a different
treatment site.
"Morphogenic protein stimulatory factor (MPSF)" refers
to a factor that is capable of stimulating the ability of a
morphogenic protein to induce tissue formation from a progenitor cell. The MPSF may have a direct or indirect effect on
enhancing morphogenic protein inducing activity. For
example, the MPSF may increase the bioactivity of another
MPSF. Agents that increase MPSF bioactivity include, for
example, those that increase the synthesis, half-life, reactivity
with other biomolecules such as binding proteins and receptors, or the bioavailability of the MPSF.
"Osteogenic protein (OP)" refers to a morphogenic protein
that is capable of inducing a progenitor cell to form cartilage
and/or bone. The bone may be intramembranous bone or
endochondral bone. Most osteogenic proteins are members of
the BMP protein family and are thus also BMPs. As described
elsewhere herein, the class of proteins is typified by human
osteogenic protein (hOP-1 ). Other osteogenic proteins useful
in the practice of the invention include osteogenically active
forms ofOP-1, OP-2, OP-3, BMP-2, BMP-3, BMP-4, BMP5, BMP-6, BMP-9, DPP, Vgl, Vgr, 60A protein, GDF-1,
GDF-3, GDF-5, GDF-6, GDF-7, BMP-10, BMP-11, BMP13, BMP-15, UNIVIN, NODAL, SCREW, ADMP or NEURAL and amino acid sequence variants thereof. In one currently preferred embodiment, osteogenic protein includes
any one of: OP-1, OP-2, OP-3, BMP-2, BMP-4, BMP-5,
BMP-6, BMP-9, and amino acid sequence variants and
homologs thereof, including species homologs thereof. Par-
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ticularly preferred osteogenic proteins are those comprising
an amino acid sequence having at least 70% homology with
the C-terminal 102-106 amino acids, defining the conserved
seven cysteine domain, of human OP-1, BMP-2, and related
proteins. Certain preferred embodiments of the instant invention comprise the osteogenic protein, OP-1. As further
described elsewhere herein, the osteogenic proteins suitable
for use with applicants' invention can be identified by means
of routine experimentation using the art-recognized bioassay
described by Reddi and Sampath (Sampath et al., Proc. Natl.
Acad. Sci., 84, pp. 7109-13, incorporated herein by reference).
Proteins useful in this invention include eukaryotic proteins identified as osteogenic proteins (see U.S. Pat. No.
5,011,691, incorporated herein by reference), such as the
OP-1, OP-2, OP-3 and CBMP-2 proteins, as well as amino
acid sequence-related proteins, such as DPP (from Drosophila), Vgl (from Xenopus), Vgr-1 (from mouse), GDF-1
(from humans, see Lee, PNAS, 88, pp. 4250-4254 (1991)),
60A (from Drosophila, see Wharton et al. PNAS, 88, pp.
9214-9218 (1991)), dorsalin-1 (from chick, see Basler et al.
Cell 73, pp. 687-702 (1993) and GenBank accession number
L12032) and GDF-5 (from mouse, see Storm et al. Nature,
368, pp. 639-643 (1994)). The teachings of the above references are incorporated herein by reference. BMP-3 is also
preferred. Additional useful proteins include biosynthetic
morphogenic constructs disclosed in U.S. Pat. No. 5,011,691,
incorporated herein by reference, e.g., COP-1, COP-3, COP4, COP-5, COP-7 and COP-16, as well as other proteins
known in the art. Still other proteins include osteogenically
active forms ofBMP-3b (see Takao, et al. Biochem. Biophys.
Res. Comm., 219, pp. 656-662 (1996)). BMP-9 (see W095/
33830), BMP-15 (see W096/35710), BMP-12 (see W095/
16035), CDMP-1 (see WO 94/12814), CDMP-2 (see W094/
12814), BMP-10 (see W094/26893), GDF-1 (see W092/
00382), GDF-10 (see W095/10539), GDF-3 (see W094/
15965) and GDF-7 (see W095/01802). The teachings of the
above references are incorporated herein by reference. Some
examples of suitable growth factors include erythropoietin,
thrombopoietin, PDGF, G-CSF, GM-CSF, IGF, TGF~,
VEGF, LIF, CNTF, FGF, EGFand BMP (bone morphogenic
protein).
"Repair" is intended to mean new bone and/or cartilage
formation which is sufficient to at least partially fill the void or
structural discontinuity at the defect. Repair does not, however, mean, or otherwise necessitate, a process of complete
healing or a treatment which is 100% effective at restoring a
defect to its pre-defect physiological/structural/mechanical
state.
"Synergistic interaction" refers to an interaction in which
the combined effect of two or more agents is greater than the
algebraic sum of their individual effects.

non-porous and may be fashioned into a desired shape. For
example, the material can be in the form of a structurally
stable, three dimensional implant. The structurally stable,
three dimensional implant can be, for example, a cube, cylinder, block or an appropriate anatomical form.
In preferred embodiments, the average pore size of the
biocompatible material is in the range of 20-500 µm. In a
preferred embodiment, the pore size is 20-190 µm. In another
embodiment, the pore size is in the range of 20-95 µm. These
pores provide residence spaces for the culturing of stem cells
and for any infiltrating osteolytic cells and osteoblasts when
the biocompatible material is embedded in the living body. In
one embodiment, the pores are spherical and uniformly distributed. Spherical pores having an average diameter in the
range of 20-500 µmare appropriate for osteoblast infiltration.
Spherical pores also provide the porous body with the necessary mechanical strength during the period that new bone is
being synthesized, thus preventing the bone from fracturing
during this period. Since stem cells are capable of differentiating into variety of cells according to the environmental
cues, this technology provides not only the interface between
the biomaterial and host tissue, but also accelerates the healing of the wound. Furthermore, there is no ethical or immunorejection issue, which associate with fetal or embryonic
stem cell technologies, because the source of the cells is the
patient tissue. Since stem cells provide an interface between
the host and biomaterial, the invention can be applied to
virtually any kind of tissue replacement.
As known by those having ordinary skill in the art, chemically, most of the rare earth (RE) elements (atomic numbers
57 through 71) are trivalent. Cerium alone is known to form
compounds with a valence of +4, such as Ce0 2 (ceria).
Cerium is believed to be a unique material with regard to the
mixed valence states provided, both +3 and +4. However, at
least with regard to cerium oxide compounds, the vast majority of valence states are +4 states.
Cerium of valence +3 is generally referred to as cerous,
while with valence +4 is generally referred to as eerie. Cerium
oxide includes both eerie oxide and cerous oxide. Cerous
oxide is also known as Cerium III oxide and has the formula
Ce 2 0 3 . Ceric oxide is known as ceria, cerium dioxide and
cerium IV oxide and has the chemical formula Ce0 2 .
The cerium oxide nanoparticles used with the invention
have an average particle size <20 nm, preferably in the range
from 1 to 10 nanometers, such as 3 to 7 nm. The inventors
have found that an average cerium oxide nanoparticle size in
the range <20 nm provides an unexpected and highly beneficial result which is believed to be based on an increased
percentage of +3 valence states (relative to the generally more
numerous +4 states) on the cerium oxide nanoparticles surface. The increasing percentage of +3 valence states is
believed to increase as the cerium oxide nanoparticle size
decreases in this size range. Surprisingly, the inventors have
found that ceria ions in a reduced stated has lead to unexpected and surprising results with respect to cell attachment
and growth. The reduced state of ceria molecules provides
excellent results with respect to the growth of cells. Growth of
cells increases with the reduced surface state of ceria.
The thickness range for the cerium oxide nanoparticles
layer is preferably 100 to 300 nm, but can be thickerorthinner
than this range, such as 20 nm to 1 µm. The cerium oxide
nanoparticle layer is also preferably porous. The surfactant
used in the reverse micelle process described below helps
keeps the cerium oxide nanoparticles separate to provide a
porous layer. The cerium oxide nanoparticles can be doped
using trivalent elements, such as rare earth elements, such as
La and Nd, which may increase the concentration ofvacan-

Biocompatible Material
The invention provides the ability to coat the biomaterial
surface with attached living stem cells isolated from adult
tissue, bone marrow. Since stem cells are capable of differentiating into variety of cells according to the environmental
cues, this technology provides both the interface between the
biomaterial and host tissue, but also provides acceleration in
the heeling of the wound. Furthermore, there is no ethical or
immunorejection issues, which associate with fetal or embryonic stem cell technologies, because the source of the cells is
the patient's tissue, or an immunological matched cells.
In a preferred embodiment, the biocompatible material
comprises a rare earth stabilized zirconia, preferably being
ceria stabilized. The biocompatible material can be porous or
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cies. The concentration range for trivalent doping elements is
generally up to about 40 wt %.
Ceria nanoparticles are presently available commercially
in the average size range from about 7 to 20 nm. However,
such particles are formed from a high temperature process
which renders the ceria nanoparticles highly agglomerated.
For use with the invention, cerium oxide nanoparticles particles are preferably obtained in a non-agglomerated state. A
reverse-micelle process using unique reagents can be used to
form substantially non-agglomerated cerium oxide nanoparticles for use with the invention. Such a process also provides
cerium oxide nanoparticles having an average size down to
about 2 nm.
By modifying the process parameters, controlled porosity
on the surface of the biocompatible material, acts as scaffolding.
The biocomposite is generally described relative to bone.
However, biocomposites according to the invention can also
be applied to other types of tissue, such as a tendon, a cartilage, a disk, a meniscus, a muscle, a tooth, a hair, a joint, and
a ligament, or a combination thereof.

ness, but are tough to machine in the dense state. In contrast,
porous plasma manufactured near-net-shape ceramics have
been found to be relatively easy to machine. The benefits of
plasma sprayed ceria-stabilized zirconia are expressed in
good corrosion resistance and excellent phase stability at high
temperatures. At present, High Isostatic Pressing (HIP),
Laser Direct Consolidation, and Plasma Spray Forming
(PSF) are considered promising nanomaterial consolidation
processes having a few limitations. The disadvantages of the
HIP are the size limitation and the complexity of the sample
geometry. The inconvenience of the laser process lies in the
constraint of material selection. However, one can flow practically all types of materials which can melt in a plasma flame.
Plasma Spray Forming (PSF) is a preferred process for the
invention since it is one of the most versatile methods of
designing large scale nanocomponents with the preferred
form and size in minimal time.
The plasma spray gun for plasma spray forming includes a
water cooled copper anode and a tungsten cathode. Due to the
applied high voltage an arc is created between them. As a
result, the flowing gases (Ar and He) reach excessive temperatures, dissociate and ionize to form plasma. Powders are
fed into the plasma where they can be melted in a control
fashion, accelerated to supersonic speeds, and directed
toward a rotating mandrel which is rapidly cooled to form a
desired shape and size. Thus, the success of the process lies in
the design of the mold mandrel material and the plasma spray
parameters, which need to be standardized for each component.
The near-net-shape processing using PSF involves simultaneous control of powder melting and then particle acceleration for deposition on a rotating mandrel or substrate with a
proper CTE (coefficient of thermal expansion) to release the
parts after cooling. Yet, for the purpose of near-net shape
component manufacturing using plasma spray a smooth surface and the correct type material mandrel is of great importance.
In general, the residual stresses generated during plasma
spraying are highly dependent of the nature of the sprayed
material and the substrate. For example, the difference of the
thermal expansion coefficient between the mandrel and the
deposited material creates a state of stress in the system. Ifthis
stress exceeds the adhesive bonding strength of the coating
with the substrate and the cohesive bonding between the
particles, the deposition will delaminate from the substrate.
However, the inventors use this known "drawback" toward a
process known as free-form part manufacturing.
In an embodiment of the invention, a preferably porous
biocompatible material has autologous stem cells attached to
its surface. The porous nature allows stem cells to be seeded
both in the biocompatible material and attached on the surface. Regarding the stem cells, the cells can be whole marrow,
isolated stem cells and/or isolated mesenchymal stem cells
for repair of segmental defects, spinal fusions or non-unions
and other bone defects. Custom cell-matrix implants containing autologous, allogeneic or xenogeneic bone marrow and/
or mesenchymal stem cells (MSCs) can be administered
using open surgical techniques, arthroscopic techniques or
percutaneous injection.
Human mesenchymal stem cells (hMSCs) can be provided
as either homogeneous, culture-expanded preparations
derived from whole-marrow (or other pre-natal or post-natal
source of autologous or allogeneic hMSCs ), from hMSCenriched or heterogeneous cultures containing an effective
dose of at least about 103 and preferably at least about 105 ,
preferably about 104 or up to 10 6 , MSCs per milliliter of the
composition. In a preferred embodiment, MSC therapy, is to
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Ceria Embodiment
As noted above, the biocompatible material preferably
comprises a rare earth stabilized zirconia, most preferably
being ceria stabilized zirconia. Ceria has been found by the
inventors to have advantages over other material for stabilizing zirconia. Of the various zirconia ceramics currently available, ceria stabilized zirconia is the most stable against degradation under humid conditions and against leaching in
aqueous environments, including body fluids. In addition,
zirconium oxide, when used in conjunction with ceria provides unique oxygen ion conduction properties. To date, ceria
stabilized zirconia has been widely used as a coating with
excellent catalytic properties, such as a thermal barrier. However, there are no reported applications of ceria-stabilized
zirconia for biomedical applications, such as for stem cell
growth according to the invention. It should be noted the
Ceria-stabilized Zirconia material is a biocompatible material, and the Ceria by itself has been widely used in other
biomedical applications as well.
Cerium oxide is largely studied due to its unique properties
as oxygen storage material. The valence change Ce+4 to Ce+ 3
and vice versa especially in the nanomaterials has been found
beneficial for multiple applications of the cerium oxide.
The chemical reaction of the transformation mechanism
can be expressed as:
2Ce•4 +2e-(from the leaving Oxygen atom)~2ce• 3

The mechanism of transformation can be explained with
the following: In the Ce0 2 (Ce+4 ) there are two extra electrons
on the Oxygen p-bands. When the oxygen atom leaves (creates vacancy) these two electrons are "left behind". The two
electrons from each oxygen atom find the lowest possible
empty energy state, which is the f-band of Ce. Each Ce atom
acting as a host for the "left behind" Oxygen electrons contribute to the localization of these electrons and each Ce+4
with the addition of an electron from the Oxygen atoms may
be transformed to the Ce+ 3 ions. Since the vacancy formation
in the interior of the particles is considered unstable process,
they tend to move more toward the surface.
As noted above, in a preferred embodiment, the biocomposite article is formed using near-net shape nanomanufacturing. In general, using conventional processing, ceramics
are sintered from stabilized zirconia powders. The resulting
materials generally provide high strength and fracture tough-
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provide that number of enriched or culture-expanded mesenchymal stem cells to the patient, or about the same number in
an optimized medium, which repairs the bone or other tissue
defect beyond that in a volume of whole marrow equivalent to
that of the defect. This is referred to as the "Regenerative
MSC Threshold", or that concentration ofMSCs necessary to
achieve direct repair of the tissue defect. The Regenerative
MSC Threshold will vary by: 1) type of tissue (i.e., bone,
cartilage, ligament, tendon, muscle, marrow stroma, dermis
and other connective tissue); 2) size or extent of tissue defect;
3) formulation with pharmaceutical carrier; and 4) age of the
patient.
In one preferred embodiment, the population of stem cells
is purified. A purified population of stem cells contains a
significantly higher proportion of stem cells than the crude
population of cells from which the stem cells are isolated. For
example, the purification procedure should lead at least to a
five fold increase, preferably at least a ten fold increase, more
preferably at least a fifteen fold increase, most preferably at
least a twenty fold increase, and optimally at least a twentyfive fold increase in stem cells with respect to the total population. The purified population of stem cells should include at
least 15%, preferably at least 20%, more preferably at least
25%, most preferably at least 35%, and optimally at least 50%
of stem cells.
Various techniques may be employed to separate the cells
by initially removing cells of dedicated lineage. Monoclonal
antibodies are particularly useful for identifying markers
associated with particular cell lineages and/or stages of differentiation.
If desired, a large proportion of terminally differentiated
cells may be removed by initially using a "relatively crude"
separation. For example, magnetic bead separations may be
used initially to remove large numbers oflineage committed
cells. Desirably, at least about 80%, usually at least 70% of the
total hematopoietic cells will be removed.
Procedures for separation may include but are not limited
to, magnetic separation, using antibody-coated magnetic
beads, affinity chromatography, cytotoxic agents joined to a
monoclonal antibody or used in conjunction with a monoclonal antibody, including but not limited to, complement and
cytotoxins, and "panning" with antibody attached to a solid
matrix, e.g., plate, elutriation or any other convenient technique.
Techniques providing accurate separation include but are
not limited to, flow cytometry, which can have varying
degrees of sophistication, e.g., a plurality of color channels,
low angle and obtuse light scattering detecting channels,
impedance channels, etc.
In adults, the large majority of pluripotent hematopoietic
stem cells are found in the bone marrow. However, small but
significant numbers of such cells can be found in the peripheral circulation, liver, spleen and cord blood. Human hematopoietic stem cells for use in the present invention may be
derived from human bone marrow, human newborn cord
blood, fetal liver or adult human peripheral blood, after
appropriate mobilization.
The frequency ofhematopoietic stem cells can be dramatically increased by treatment of a subject with certain compounds including cytokines. Such "mobilized" peripheral
blood hematopoietic stem cells have become an important
alternative to bone marrow-derived hematopoietic stem cells
transplantation procedures primarily because engraftment is
more rapid. (See, e.g., Tanaka, J, et al., Int J Hematol 69(2):
70-4, 1999.)
Such mobilization may be accomplished using for
example, one or more of granulocyte colony-stimulating fac-

tor (G-CSF), stem cell factor (SCF), thrombopoietin (Tpo),
and a chemotherapeutic agent (i.e., cyclophosphamide), or a
small molecule, such as AMD 3100, a CXCR4 agonist.
Numerous methods for human hematopoietic stem cell
enrichment/isolation are known in the art and generally
include obtaining bone marrow, newborn cord blood, fetal
liver or adult human peripheral blood which contains hematopoietic stem cells. Once obtained, a hematopoietic stem cell
population may be enriched by performing various separation
techniques such as density gradient separation, immunoaffinity purification using positive and/or negative selection by
panning, FACS or magnetic bead separation. Following such
enrichment steps, the cell population is further characterized
phenotypically and functionally.
Hematopoietic stem cells (HSC) are initially characterized
by immunophenotype, e.g., as lineage negative and either (1)
CD34+/Thyl + or(2) CD 34+/CD38- cells thatare also KDR+.
Human HSC may also be characterized by telomere length,
where cells with high proliferative capacity have longer
telomeres. In general, a population of cells is considered to be
enriched for human HSC if greater than 0.1 % of the CD 34 +
cells have the immunophenotype, CD 34+ CD38- KDR+ or
CD34+ Thyl.
Preferredcytokines forthe culture ofhumanhematopoietic
stem cells include one or more of interleukin-3 (IL-3), interleukin-6 (IL-6), interleukin-11 (IL-11 ), interleukin-12 (IL12) stem cell factor (SCF), fms-like tyrosine kinase-3 (flt-3),
transforming growth factor-.beta. (TGF-.beta.), an early acting hematopoietic factor, described, for example in WO
91/05795, and thrombopoietin (Tpo).
Human adult hematopoietic stem cells are mostly quiescent or slow cycling. However, it has been demonstrated that
when human stem cells are cultured under conditions which
include exogenously provided cytokines, wherein TGF-~ 1 is
blocked; quiescent, hematopoietic multipotent progenitors
grow in a short term culture assay in which the cells do not
grow when TGF-~ 1 is not blocked.
Molecules used for isolating populations of stem cells are
advantageously conjugated with labels that expedite identification and separation. Stem cell specific molecules include,
but not limited to: CXCR4, CD 133, SCA-1, Tra-1-60, CD44,
CD 73, CD 90, CD 105 and Stro-1. Examples of labels
include magnetic beads; biotin, which may be identified or
separated by means of its affinity to avidin or streptavidin;
fluorochromes, which may be identified or separated by
means of a fluorescence-activated cell sorter (FACS, see
below), and the like. Any technique may be used for isolation
as long as the technique does not unduly harm the stem cells.
Many such methods are known in the art.
In one embodiment, the binding molecule is attached to a
solid support. Some suitable solid supports include nitrocellulose, agarose beads, polystyrene beads, hollow fiber membranes, magnetic beads, and plastic Petri dishes. For example,
the binding molecule can be covalently linked to Pharmacia
Sepharose 6 MB macro beads. The exact conditions and
duration of incubation for the solid phase-linked binding
molecules with the crude cell mixture will depend upon several factors specific to the system employed, as is well known
in the art.
Cells that are bound to the binding molecule are removed
from the cell suspension by physically separating the solid
support from the remaining cell suspension. For example, the
unbound cells may be eluted or washed away with physiologic buffer after allowing sufficient time for the solid support to bind the stem cells. The bound cells are separated from
the solid phase by any appropriate method, depending mainly
upon the nature of the solid phase and the binding molecule.
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For example, bound cells can be eluted by enzymatically
"nicking" or digesting an enzyme-sensitive "spacer"
sequence between the solid phase and an antibody (e.g., antibodies directed to: CXCR4, CD 133, SCA-1, Tra-1-60, CD
44, CD 73, CD 90, CD 105 and Stro-1). Suitable spacer
sequences bound to agarose beads are commercially available
from, for example, Pharmacia.
The eluted, enriched fraction of cells may then be washed
with a buffer by centrifugation and preserved in a viable state
at low temperatures for later use according to conventional
technology. The cells may also be used immediately, for
example by being infused intravenously into a recipient.
Methods for removing unwanted cells by negative selection are also known. For example, unwanted cells in a starting
cell population are labeled by an antibody, or by a cocktail of
antibodies, to a cell surface protein characteristic of Lin+
cells. The unwanted antibody-labeled cells are removed by
methods known in the art. For example, the labeled cells can
be immobilized on a colunm that binds to the antibodies and
captures the cells.
Alternatively, the antibody that binds the cell surface proteins can be linked to magnetic colloids for capture of
unwanted cells on a colunm surrounded by a magnetic field.
This system is currently available through StemCell Technologies Inc., Vancouver, British Columbia, Canada. The
remaining cells that flow through the colunm for collection
are enriched in cells that do not express the cell surface
proteins that the tetrameric antibodies were directed against.
The antibody cocktail that can be used to deplete unwanted
Lin+ cells can be custom made to include antibodies against
lineage specific markers, such as, for example, CD2, CD3,
CD4, CDS, CDS, CDlO, CD! lb, CD13, CD14, CD15, CD16,
CD19, CD20, CD24, CD25. CD28, CD29, CD33, CD36,
CD38, CD41, CD56, CD66b, CD66e, CD69, and glycophorin A. The desired cells that lack these markers are not
lineage committed, i.e. Lin-.
In a preferred embodiment, a labeled binding molecule is
bound to the stem cells, and the labeled cells are separated by
a mechanical cell sorter that detects the presence of the label.
The preferred mechanical cell sorter is a fluorescence activated cell sorter (FACS). FACS machines are commercially
available. Generally, the following FACS protocol is suitable
for this procedure: a Coulter Epics Eliter sorter is sterilized by
running 70% ethanol through the systems. The lines are
flushed with sterile distilled water. Cells are incubated with a
primary antibody diluted in Hank's balanced salt solution
supplemented with 1% bovine serum albumin (HB) for 60
minutes on ice. The cells are washed with HB and incubated
with a secondary antibody labeled with fluorescein isothiocyanate (FITC) for 30 minutes on ice. The secondary label
binds to the primary antibody. The sorting parameters, such as
baseline fluorescence, are determined with an irrelevant primary antibody. The final cell concentration is usually set at
one million cells per ml. While the cells are being labeled, a
sort matrix is determined using fluorescent beads as a means
of aligning the instrument. Once the appropriate parameters
are determined, the cells are sorted and collected in sterile
tubes containing medium supplemented with fetal bovine
serum and antibiotics, usually penicillin, streptomycin and/or
gentamicin. After sorting, the cells are re-analyzed on the
FACS to determine the purity of the sort.
Any cell can be used in the methods of the invention,
including but not limited to, stem cells, thymocytes, precursor
cells and the like. A precursor cell population includes cells of
a mesodermal derived cellular lineage, more particularly of

hematopoietic lineage, bone lineage, endothelial lineage,
muscle cell lineage, epithelial cell lineage and neural cell
lineage.
A "precursor cell" can be any cell in a cell differentiation
pathway that is capable of differentiating into a more mature
cell. As such, the term "precursor cell population" refers to a
group of cells capable of developing into a more mature cell.
A precursor cell population can comprise cells that are totipotent, cells that are pluripotent and cells that are stem cell
lineage restricted (i.e. cells capable of developing into less
than all hematopoietic lineages, or into, for example, only
cells of erythroid lineage). As used herein, the term "totipotent cell" refers to a cell capable of developing into all lineages of cells. Similarly, the term "totipotent population of
cells" refers to a composition of cells capable of developing
into all lineages of cells. Also as used herein, the term "pluripotent cell" refers to a cell capable of developing into a
variety (albeit not all) lineages and are at least able to develop
into all hematopoietic lineages (e.g., lymphoid, erythroid,
and thrombocytic lineages). For example, a pluripotent cell
can differ from a totipotent cell by having the ability to
develop into all cell lineages except endothelial cells. A
"pluripotent population of cells" refers to a composition of
cells capable of developing into less than all lineages of cells
but at least into all hematopoietic lineages. As such, a totipotent cell or composition of cells is less developed than a
pluripotent cell or compositions of cells. As used herein, the
terms "develop", "differentiate" and "mature" all refer to the
progression of a cell from the stage of having the potential to
differentiate into at least two different cellular lineages to
becoming a specialized cell. Such terms can be used interchangeably for the purposes of the present application.
As used herein, the term "population" refers to cells having
the same or different identifying characteristics. The term
"lineage" refers to all of the stages of the development of a
cell type, from the earliest precursor cell to a completely
mature cell (i.e. a specialized cell).
A stem cell population of the present invention is capable
of developing into cells of mesodermal cell lineage, of ectodermal cell lineage or of endodermal cell lineage. As used
herein, mesodermal cells include cells of connective tissue,
bone, cartilage, muscle, blood and blood vessel, lymphatic
and lymphoid organ, notochord, pleura, pericardium, peritoneum, kidney and gonad. Ectodermal cells include epidermal
tissue cells, such as those of nail, hair, glands of the skin, the
nervous system, the external sense organs (e.g., eyes and ears)
and mucous membranes (such as those of the mouth and
anus). Endodermal cells include cells of the epithelium such
as those of the pharynx, respiratory tract (except the nose),
digestive tract, bladder and urethra cells. Preferred cells
within a stem cell population of the present invention include
cells of at least one of the following cellular lineages: hematopoietic cell lineage, endothelial cell lineage, epithelial cell
lineage, muscle cell lineage and neural cell lineage. Other
preferred cells within a stem cell population of the present
invention include cells of erythroid lineage, endothelial lineage, leukocyte lineage, thrombocyte lineage, erythroid lineage (including primitive and definitive erythroid lineages),
macrophage lineage, neutrophil lineage, mast cell lineage,
megakaryocyte lineage, natural killer cell lineage, eosinophil
lineage, T cell lineage, endothelial cell lineage and B cell
lineage.
The biocompatible material may be cultured with any variety of cells. A "cell", according to the present invention, is any
preparation ofliving tissue, including primary tissue explants
and preparations thereof, isolated cells, cells lines (including
transformed cells), and host cells. Preferably, autologous
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cells are employed, but xenogeneic, allogeneic, or syngeneic
The present invention is not limited to the use of tissuecells are also useful. Where the cells are not autologous, it
producing cells. Certain preferred embodiments of the invenmay be desirable to administer immunosuppressive agents in
tion utilize such cells, primarily because the biocompatible
order to minimize rejection. In preferred embodiments, such
material is so well suited to tissue-regeneration applications
agents may be included within the cell composition to ensure
(particularly with those involving growth of bone and/or careffective local concentrations of the agents and to minimize
tilage). Any cell may be cultured or seeded into the biocomsystemic effects of their administration. The cells employed
patible material of the invention. In some cases, it will be
desirable to include other cells in addition with tissue-promay be primary cells, explants, or cell lines, and may be
dividing or non-dividing cells. Cells may be expanded exducing cells.
vivo prior to introduction to the biocompatible material. 10
The cells that are cultured or seeded into the biocompatible
Autologous cells are preferably expanded in this way if a
material may be genetically engineered, for example to prosufficient number of viable cells cam10t be harvested from the
duce a protein or other factor that it useful in the particular
host.
application. In preferred embodiments, cells may be engineered to produce molecules that impart resistance to host
Any preparation of living cells may be used with the biocompatible material of the present invention. For example, 15 immune attack and rejection. The Fas-Land CR-1 genes are
examples of useful such genes.
cultured cells or isolated individual cells may be used. AlterIn one preferred embodiment, the biocompatible material
natively or additionally, pieces of tissue, including tissue that
is coated or pre-treated with cell-adhesion molecules to prohas some internal structure, may be used. The cells may be
vide for enhanced cell attachment. Examples of cell adhesive
primary tissue explants and preparations thereof, cell lines
(including transformed cells), or host cells. Where the cells 20 proteins, protein fragments, or peptides, include, but not limited to fibronectin, laminin, collagen, vitronectin, osteoponare host cells and are introduced into the biocompatible matetin, RGD peptides, RGDS peptides, YIGSR peptides, ICAMrial in vivo, preferred sources of cells include, but are not
1, PECAM-1, LFA-3, LFA-1, VLA-4, VLA-5, L-Selectinand
limited to, the inner layerof the periosteum or perichondrium,
HCAM. Bone tissue-specific collagen (e.g., Type I collagen)
blood or other fluids containing the cells of choice, and damaged host tissue particularly bone or cartilage) that includes 25 derived from a number of sources are also suitable, including
soluble collagen, acid-soluble collagen, collagen soluble in
such cells.
neutral or basic aqueous solutions, as well as those collagens
Any available methods may be employed to harvest, mainwhich are commercially available. In addition, Type II coltain, expand, and prepare cells for use in the present invenlagen, as found in cartilage, also may be used in combination
tion.Useful references that describe such procedures include,
for example, Freshney, Culture of Animal Cells: a Manual of 30 with Type I collagen.
The coating procedure may include the preliminary coatBasic Technique, Alan R. Liss Inc., New York, N.Y., incoring of the biocompatible material with a fibrin matrix, folporated herein by reference.
lowed by deposition thereon of fibronectin. Alternatively, the
The biocompatible material of the invention is useful as a
fibronectin may be incorporated into the fibrin matrix by
scaffold for production of hard or soft tissues. Tissue-producing or -degrading cells that may be incorporated into the 35 depositing a mixture of fibrinogen and fibronectin on the
surfaces of the biocompatible material followed by treatment
material include, but are not limited to, chondrocytes, osteowith thrombin to convert fibrinogen to fibrin in situ. In fact,
cytes, osteoblasts, osteoclasts, mesenchymal stem cells, other
fibrinogen is commonly available from lyophilized cryoprebone- or cartilage-producing cells or cell lines, fibroblasts,
cipitate (obtained during blood protein fractionation) which
muscle cells, hepatocytes, parenchymal cells, cells of intes40 also contains amounts of fibronectin. F ibrin-fibronectin coattinal origin, nerve cells, and skin cells.
ings show good stem cell adhesion.
Methods of isolating and culturing such tissue-producing
Further examples of cell-adhesion molecules include:
or -degrading cells, and/or their precursors, are known in the
Immunoglobulin Gene Superfamily-ICAM-1 (CD54),
art (see, for example, Vacanti et al., U.S. Pat. No. 5,041,138;
LFA-1, PECAM-1 (CD31), LFA-3 (CD58), LFA-2; Integrin
Elgendy et al., Biomater. 14:263, 1993; Laurencin et al, J. 45
Family-~ 1 VLA subfamily, VLA-4 (CDw49d/CD29),
Biomed. Res. 27:963, 1993; Freed et al., J. Cell. Biochem.
Fibronectin, VLA-5 (CDw49e/CD29), Fibronectin SAM!,
51:257, 1993; Atala et al., J. Ural. 150:745, 1993; Ishaug et
~ 2 leukocyte adhesion subfamily, LFA-1 (CD1 la/CD18),
al., J. Biomed. Mater. Res. 28:1445, 1994; Chu et al., J.
ICAMl/2, ~ 3 cytoadhesion subfamily, Vitronectin, VitronecBiomed. Mater. Res. 29:1147, 1995; Thomson et al., J. Biotin receptor (CD51/CD61 ); Selectin Family-L-Selectin, Promater. Sci. Polymer Edn. 7:23, 1995, each of which is incor5o teoglycanAnalogues, HCAM (CD44), Collagen, Hyaluronic
porated by reference).
Acid; CD36/LIMP II Family-Thrombospondin, Collagen.
For example, mesenchymal stem cells, which can differStem Cell Compositions
entiate into a variety of mesenchymal or connective tissues
(including, for example, adipose, osseous, cartilagenous,
In a preferred embodiment, the isolated stem cells are
elastic, and fibrous connective tissues), can be isolated, puri- 55 contacted with a vector expressing a desired molecule. The
molecule can be a growth factor, chemokine, cell specific
fied, and replicated according to known techniques (see
maturation factor, cell differentiation factor and the like.
Caplan et al., U.S. Pat. No. 5,486,359; Caplan et al., U.S. Pat.
Examples of genes useful for introduction into isolated stem
No. 5,226,914; Dennis et al., Cell Transplantation 1:23,
1992, each of which is incorporated herein by reference).
cells include those that encode bone morphogenic proteins
Such mesenchymal cells have been studied in association 60 such as OP-1, OP-2, OP-3, COP-1, COP-3, COP-4, COP-5,
COP-7, COP-16, BMP-2, BMP-3, BMP-3b, MP-4, BMP-5,
with tricalcium phosphate and hydroxyapatite carriers and
BMP-6, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13,
have been found to be capable of successful differentiation
BMP-14, B-15, BMP-16, BMP-17, BMP-18, GDF-1, GDFfrom within such carriers (see Caplan et al., U.S. Pat. No.
2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10,
5, 197, 985, incorporated herein by reference). Similar procedures are employed to direct mesenchymal cell differentia- 65 GDF-11, GDF-12, MP121, dorsalin-1, DPP, Vg-1, Vgr-1, 6A
tion within biocompatible material scaffolds of the present
protein, NODAL, UNIVIN, SCREW, ADMP, NEURAL,
invention.
TGF-~ and conservative amino acid sequence variants
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thereof having osteogenic activity. Other examples of desired
molecules include: Factor VIII, von Willebrand factor, insulin, tissue plasminogen activator, any of the interleukins, or a
growth factor. Some examples of interleukins include IL-1,
-2, -3, -4, -5, -6, -7, -8, -9' -10, -11, -12, -13, -14, -15, -16, -17'
-18, -19, -20, and -21. Some examples of suitable growth
factors include erythropoietin, thrombopoietin, PDGF,
G-CSF, GM-CSF, IGF, TGF~, VEGF, LIF, CNTF, FGF, EGF
and BMP (bone morphogenic protein).
The stem cells can be transiently transduced, transduced
with a stably integrated vector or a self-replicating extrachromosomal vector.
In another preferred embodiment, integration of a vector
into the stem cell genome is avoided. Lack of integration into
the stem cell genome is accomplished by using plasmid DNA
or messenger RNA. As an illustrative example, the expression
of the endogenous gene within the stem cell genome is activated using either small molecules derived from a chemical
library and screened for specific activation of the desired gene
and/or adding a recombinant protein or peptide that transcriptionally activates the expression of the homing protein. The
transcriptional activation can use any transcriptional activator, for example, a zinc finger-transcription activator (additional DNA binding protein motifs include helix-tum-helix
and leucine zipper) fusion protein or a specific transcription
activator protein that binds to the enhancer or promoter region
responsible for controlling expression of the homing protein.
Examples of homing genes that could influence differentiation include but not limited to: SCG 10; Na Channel II; glut-2,
synapsin, epo, SCF, shh, wint, BMPs Ephrins, Pax-6, Emx-2,
Mash-1, jagged 1and2, notch- and 2, ephrin B2 and ephrin
B4, Bmi-1, different homeobox genes HOXB4 that regulates
the probability of stem cell renewal. Bmi-1 is expressed in
stem cells and is essential for their maintenance.
In another preferred embodiment, a gene delivery vehicle
comprises use of a non-integrating vector. By gene delivery
vehicle is meant a carrier which can deliver at least one
nucleic acid to a host cell. The nucleic acid that is delivered to
a host cell may comprise a nucleic acid sequence encoding an
amino acid sequence, such as for example, Factor VIII, Factor
IX, or mutant genes for ~-glucocerebrosidase, erythropoietin
("EPO"), a-L-iduronidase, iduronate sulphatase, N-sulphatase, N-acetyl a-D-glucosaminidase, a-glucosamine-Nacetyltransferase,
N-acetyl-a-D-glucosaminide-6-sulphatase,
Galactosamine-6
sulphate
sulphatase,
~-galactosidase, N-acetyl-alactosamine-4-sulphatase, acid
ceraminidase, acid sphingomyelinase, galactocerebroside
~-galactosidase, arylsuphataseA, adenosine deaminase, a-Lfucosidase growth factors such as the interleukin family,
angiogenesis stimulating or inhibiting factors such as the
nitric oxide synthases (NOS 1-3 ), vascular endothelial growth
factors ("VEGF"), Angiostatin 1-7. Other examples of genes
useful for introduction into isolated stem cells include those
that encode Factor VIII, von Willebrand factor, insulin, tissue
plasminogen activator, any of the interleukins, or a growth
factor. Some examples ofinterleukins include IL-1, -2, -3, -4,
-5,-6,-7,-8,-9,-10,-11,-12,-13,-14,-15,-16,-17,-18,-19,
-20, and -21. Some examples of suitable growth factors
include erythropoietin, thrombopoietin, PDGF, G-CSF, GMCSF, IGF, TGF~, VEGF, LIF, CNTF, FGF, EGF and BMP
(bone morphogenic protein). Examples of bone morphogenic
proteins include, but not limited to: OP-1, OP-2, OP-3, COP1, COP-3, COP-4, COP-5, COP-7, COP-16, BMP-2, BMP-3,
BMP-3b, MP-4, BMP-5, BMP-6, BMP-9, BMP-10, BMP11, BMP-12, BMP-13, BMP-14, B-15, BMP-16, BMP-17,
BMP-18, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-7,
GDF-8, GDF-9, GDF-10, GDF-11, GDF-12, MP121, dorsa-

lin-1, DPP, Vg-1, Vgr-1, 6 A protein, NODAL, UNIVIN,
SCREW, ADMP, NEURAL, TGF-~ and conservative amino
acid sequence variants thereof having osteogenic activity.
The nucleic acid may further comprise at least one promoter,
and/or enhancer, and/or terminator. It may also comprise
transcription initiation sites, and the like. By delivering a
nucleic acid to a host cell, the nucleic acid is moved from the
outside to the inside of the host cell. Transient expression of
the transgene is sufficient to trigger cells to differentiate into
the desired mature tissue cells. Therefore, a preferred nonintegrating vector is adenovirus (adenovirus has other affects
on the cells, such as immunostimulatory properties that may
results in elimination of the infected cell.) or non-replicating,
non-integrating plasmids.
A non-replicating, non-integrating plasmid is a nucleic
acid which when transfected into a host cell does not replicate
and does not specifically integrate into the host cell's genome
(i.e. does not integrate at high frequencies and does not integrate at specific sites). In other preferred embodiments, the
plasmid is non-integrating but does replicate and can be used
in those instances where larger numbers of transduced cells
are required.
Replicating plasmids can be identified using standard
assays including the standard replication assay ofU stav et al.,
EMBO J., 10, 449-457, 1991. A potential stabilized episome
plasmid is derived from the Epstein bar virus gene, EBNA-1,
that causes the plasmid to exist as an episome but is limited to
B cell lineages.
In other preferred embodiments, a non-replicating, nonintegrating plasmid is used. This type of plasmid cannot be
stably maintained in cells, independently of genomic DNA
replication, and which does not persist in progeny cells for
three or more cell divisions without a significant loss in copy
number of the plasmid in the cells, i.e., with a loss of greater
than an average of about 50% of the plasmid molecules in
progeny cells between a given cell division. Generally, in
self-replicating vectors, the self-replicating function is provided by using a viral origin of replication and providing one
or more viral replication factors that are required for replication mediated by that particular viral origin. The term "transiently transfecting, non-integrating plasmid" herein means
the same as the term "non-replicating, non-integrating plasmid" as defined above.
Preferably the plasmid is a naked nucleic acid. As used
herein, the term "naked" refers to a nucleic acid molecule that
is free of direct physical associations with proteins, lipids,
carbohydrates or proteoglycans, whether covalently or
through hydrogen bonding. The term does not refer to the
presence or absence of modified nucleotides or ribonucleotides, or chemical modification of the all or a portion of a
nucleic acid molecule by such means as methylation or the
inclusion of protecting groups or cap- or tail structures.
In a preferred embodiment, a non-integrating vector comprises a nucleic acid encoding for any one of: Factor VIII,
Factor IX, or mutant genes for ~-glucocerebrosidase, erythropoietin ("EPO"), a-L-iduronidase, iduronate sulphatase,
N-sulphatase, N-acetyl a-D-glucosaminidase, a-glucosamine-N-acety ltransferase,
N-acety l-a-D-glucosaminide-6-sulphatase, Galactosamine-6 sulphate sulphatase,
~-galactosidase,
N-acetyl-alactosamine-4sulphatase, acid ceraminidase, acid sphingomyelinase,
galactocerebroside ~-galactosidase, arylsuphatase A,
adenosine deaminase, a-L-fucosidase growth factors such as
the interleukin family, angiogenesis stimulating or inhibiting
factors such as the nitric oxide synthases (NOSl-3), vascular
endothelial growth factors ("VEGF"), Angiostatin 1-7. Other
examples of genes useful for introduction into isolated stem

10

15

20

25

30

35

40

45

50

55

60

65

US 7,888,119 B2

21

22

cells include those that encode Factor VIII, von Willebrand
factor, insulin, tissue plasminogen activator, any of the interleukins, or a growth factor. Some examples of interleukins
include IL-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, -11, -12, -13, -14,
-15, -16, -17, -18, -19, -20, and-21. Some examples of suitable growth factors include erythropoietin, thrombopoietin,
PDGF, G-CSF, GM-CSF, IGF, TGF~, VEGF, LIF, CNTF,
FGF, EGF and BMP (bone morphogenic protein). Examples
of bone morphogenic proteins include, but not limited to:
OP-1, OP-2, OP-3, COP-1, COP-3, COP-4, COP-5, COP-7,
COP-16, BMP-2, BMP-3, BMP-3b, MP-4, BMP-5, BMP-6,
BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14,
B-15, BMP-16, BMP-17, BMP-18, GDF-1, GDF-2, GDF-3,
GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11,
GDF-12, MP 121, dorsalin-1, DPP, Vg-1, Vgr-1, 6Aprotein,
NODAL, UNIVIN, SCREW, ADMP, NEURAL, TGF-~ and
conservative amino acid sequence variants thereof having
osteogenic activity. In certain embodiments, the vector comprises nucleic acids expressing targeting agents. For example,
targeting agents may include, but are not limited to, EGF,
FGF, SDF-1, transferrin, and endothelial specific peptides
and bone specific ligands or antibodies to cell surface markers, such as CD34.
In another non-limiting example, a targeting agent may
comprise an antibody, cytokine, growth factor, hormone,
lymphokine, receptor protein, such as, for example CD4
(T-helper cell surface marker), CDS (cytotoxic lymphocyte
cell surface marker) or soluble fragments thereof, a nucleic
acid which bind corresponding nucleic acids through base
pair complementarity, or a combination thereof(U.S. Pat. No.
6,071,533, incorporated herein by reference). In other
embodiments, the targeting ligand may comprise a cellular
receptor-targeting ligand, a fusogenic ligand, a nucleus targeting ligand, or a combination thereof (U.S. Pat. No. 5,908,
777, incorporated herein by reference). In another non-limiting example, the targeting ligand may comprise an integrin
receptor ligand, described in U.S. Pat. No. 6,083,741, incorporated herein by reference.
In another preferred embodiment, the vector integrates into
the stem cell genome. Preferably the vector expresses SCG
10; Na Channel II; glut-2, synapsin, epo, SCF, shh, wint,
BMPs Ephrins, Pax-6, Emx-2, Mash-1,jagged 1and2, notchand 2, ephrin B2 and ephrin B4, Bmi-1, HOXB4, Factor VIII,
Factor IX, or mutant genes for ~-glucocerebrosidase, erythropoietin ("EPO"), a-L-iduronidase, iduronate sulphatase,
N-sulphatase, N-acetyl a-D-glucosaminidase, a-glucosamine-N-acetyltransferase,
N-acety1-a-D-glucosaminide-6-sulphatase, Galactosamine-6 sulphate sulphatase,
~-galactosidase,
N-acetyl-alactosamine-4sulphatase, acid ceraminidase, acid sphingomyelinase,
galactocerebroside ~-galactosidase, arylsuphatase A,
adenosine deaminase, a-L-fucosidase growth factors such as
the interleukin family, angiogenesis stimulating or inhibiting
factors such as the nitric oxide synthases (NOSl-3), vascular
endothelial growth factors ("VEGF"), Angiostatin 1-7. Other
examples of genes useful for introduction into isolated stem
cells include those that encode Factor VIII, von Willebrand
factor, insulin, tissue plasminogen activator, any of the interleukins, or a growth factor. Some examples of interleukins
include IL-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, -11, -12, -13, -14,
-15, -16, -17, -18, -19, -20, and-21. Some examples of suitable growth factors include erythropoietin, thrombopoietin,
PDGF, G-CSF, GM-CSF, IGF, TGF~, VEGF, LIF, CNTF,
FGF, EGF and BMP (bone morphogenic protein) and the
integration is site-specific. Examples of bone morphogenic
proteins include, but not limited to: OP-1, OP-2, OP-3, COP1, COP-3, COP-4, COP-5, COP-7, COP-16, BMP-2, BMP-3,

BMP-3b, MP-4, BMP-5, BMP-6, BMP-9, BMP-10, BMP11, BMP-12, BMP-13, BMP-14, B-15, BMP-16, BMP-17,
BMP-18, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-7,
GDF-8, GDF-9, GDF-10, GDF-11, GDF-12, MP121, dorsalin-1, DPP, Vg-1, Vgr-1, 6 A protein, NODAL, UNIVIN,
SCREW, ADMP, NEURAL, TGF-~ and conservative amino
acid sequence variants thereof having osteogenic activity.
Introducing the genes, fragments or variants thereof, into
an individual can include use of vectors, liposomes, naked
DNA, adjuvant-assisted DNA, gene gun, catheters, etc. Vectors include chemical conjugates such as described in WO
93/04701, which has a targeting moiety (e.g. a ligand to a
cellular surface receptor), and a nucleic acid binding moiety
(e.g. poly lysine), viral vector (e.g. a DNA or RNA viral vector), fusion proteins such as described in PCT/US95/02140
(WO 95/22618) which is a fusion protein containing a target
moiety (e.g. an antibody specific for a target cell) and a
nucleic acid binding moiety (e.g. a protamine), plasmids,
phage etc.
When taken up by a cell, the genetic construct(s) remain
present in the cell as a functioning extrachromosomal molecule. DNA may be introduced into cells where it remains as
separate genetic material in the form of a plasmid or plasmids.
Alternatively, RNA may be administered to the cell. It is also
contemplated to provide the genetic construct as a linear
minichromosome including a centromere, telomeres and an
origin of replication.
Vectors can include regulatory elements necessary for gene
expression of a nucleic acid molecule. The elements include:
a promoter, an initiation codon, a stop codon, and a polyadenylation signal. In addition, enhancers may be required for
gene expression of the sequence of choice, variants or fragments thereof. It is necessary that these elements be operably
linked to the sequence that encodes the desired proteins and
that the regulatory elements are operable in the individual to
whom they are administered.
Initiation codons and stop codons are generally considered
to be part of a nucleotide sequence that encodes the desired
tissue specific protein. However, it is necessary that these
elements are functional in the individual to whom the gene
construct is administered. The initiation and termination
codons must be in frame with the coding sequence.
Promoters and polyadenylation signals used must be functional within the cells of the individual. Examples of promoters useful to practice the present invention, include but are not
limited to promoters from Simian Virus 40 (SV40), Mouse
Mammary Tumor Virus (MMTV) promoter, Human Immunodeficiency Virus (HIV) such as the HIV Long Terminal
Repeat (LTR) promoter, Moloney virus, ALY, Cytomegalovirus (CMV) such as the CMV immediate early promoter,
Epstein Barr Virus (EBY), Rous Sarcoma Virus (RSV) as well
as promoters from human genes such as human Actin, human
Myosin, human Hemoglobin, human muscle creatine and
human metallothionein. Examples of polyadenylation signals
useful to practice the present invention, especially in the
production of a genetic vaccine for humans, include but are
not limited to SV40 polyadenylation signals and LTR polyadenylation signals, human growth hormone poly A signal. In
particular, the SV40 polyadenylation signal which is in
pCEP4 plasmid (Invitrogen, San Diego Calif.), referred to as
the SV40 polyadenylation signal, can be used.
In addition to the regulatory elements required for DNA
expression, other elements may also be included in the DNA
molecule. Such additional elements include, zinc fingers,
enhancers. The enhancer may be selected from the group
including but not limited to: human Actin, human Myosin,
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human Hemoglobin, human muscle creatine and viral
nology: Principles and Applications for DNA Amplification,
enhancers such as those from CMV, RSV and EBY.
H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70).
Various methods known to those skilled in the art can be
Genetic constructs can be provided with mannnalian origin
used to express nucleic acid sequences in the non-immortalof replication in order to maintain the construct extrachromoized cells. For example, the identified and isolated gene can
somally and produce multiple copies of the construct in the
be inserted into an appropriate cloning vector. A large number
cell. For example, plasmids pCEP4 and pREP4 from Invitroof vector-host systems known in the art may be used. Possible
gen (San Diego, Calif.) contain the Epstein Barr virus origin
vectors include, but are not limited to, plasmids or modified
of replication and nuclear antigen EBNA-1 coding region
viruses, but the vector system must be compatible with the
which produces high copy episomal replication without inte10 host cell used. Examples of vectors include, but are not limgration.
ited to, E. coli, bacteriophages such as lambda derivatives, or
In order to maximize protein production, regulatory
plasmids such as pBR322 derivatives or p UC plasmid derivasequences may be selected which are well suited for gene
tives, e.g., pGEX vectors, pmal-c, pFLAG, etc. The insertion
expression in the cells the construct is administered into.
into a cloning vector can, for example, be accomplished by
Moreover, codons may be selected which are most efficiently
transcribed in the cell. One having ordinary skill in the art can 15 ligating the DNA fragment into a cloning vector that has
complementary cohesive termini. However, if the compleproduce DNA constructs which are functional in the cells.
mentary restriction sites used to fragment the DNA are not
In some embodiments, the nucleic acid molecule is delivpresent in the cloning vector, the ends of the DNA molecules
ered to the cells in conjunction with administration of a facilimay be enzymatically modified. Alternatively, any site
tating agent. Facilitating agents are also referred to as polynucleotide function enhancers or genetic vaccine facilitator 20 desired may be produced by ligating nucleotide sequences
(linkers) onto the DNA termini; these ligated linkers may
agents. Facilitating agents are described in e.g. International
comprise
specific chemically synthesized oligonucleotides
Application No. PCT/US94/00899 filed Jan. 26, 1994 and
encoding restriction endonuclease recognition sequences.
International Application No. PCT/US95/04071 filed Mar.
Recombinant molecules can be introduced into host cells via
30, 1995, both incorporated herein by reference. Facilitating
agents which are administered in conjunction with nucleic 25 transformation, transfection, infection, electroporation, etc.,
so that many copies of the gene sequence are generated.
acid molecules may be administered as a mixture with the
Preferably, the cloned gene is contained on a shuttle vector
nucleic acid molecule or administered separately simultaplasmid, which provides for expansion in a cloning cell, e.g.,
neously, before or after administration of nucleic acid molE.coli, and facile purification for subsequent insertion into an
ecules.
30 appropriate expression cell line, if such is desired. For
In some preferred embodiments, the genetic constructs of
example, a shuttle vector, which is a vector that can replicate
the invention are formulated with or administered in conjuncin more than one type of organism, can be prepared for reption with a facilitator selected from the group consisting of,
lication in both E. coli and Saccharomyces cerevisiae by
for example, benzoic acid esters, anilides, amidines, urethans
linking sequences from an E. coli plasmid with sequences
and the hydrochloride salts thereof such as those of the family
35 from the yeast 2µ plasmid.
of local anesthetics. The facilitating agent is administered
Another method comprises ligating the differentiation proprior to, simultaneously with or subsequent to the genetic
tein into an artificial replicating chromosome and microinj ect
construct. The facilitating agent and the genetic construct
it into the stem cell. The percent of transformed cells may not
may be formulated in the same composition.
be important because the disease state selects for the transIn some embodiments, the genetic constructs are adminis- 40 formed stem cell. Larger numbers of stem cells may be transtered free of facilitating agents, that is in formulations free
duced if a critical mass is needed to seed the tissue replacefrom facilitating agents using administration protocols in
ment or tissue correction site.
which the genetic constructions are not administered in conIn an alternative method, the desired gene may be identified
junction with the administration of facilitating agents. (catand isolated after insertion into a suitable cloning vector in a
ionic lipid/helper lipid formulations, electroporation, ultra- 45 "shot gun" approach. Enrichment for the desired gene, for
sound, cationic polymers (PEI, poly lysine, poly-Lexample, by size fractionation, removal of highly-repetitive
ornithine), non-interacting polymers, such as Poloxamer or
sequences, subtractive or otherwise selective hybridization,
polyvinylpyrolidone ).
and other methods as may be known in the art, can be done
Nucleic acid molecules which are delivered to cells accordbefore insertion into the cloning vector.
ing to the invention may serve as genetic templates for pro- 50
The nucleotide sequence can be inserted into an appropriteins that function as tissue specific maturation agents. In
ate expression vector, i.e., a vector which contains the necespreferred embodiments, the nucleic acid molecules comprise
sary elements for the transcription and translation of the
the necessary regulatory sequences for transcription and
inserted protein-coding sequence. Such elements are termed
translation of the coding region in the cells of the animal.
herein a "promoter." Thus, the nucleic acid encoding a desired
Additionally, the nucleic acid sequences of choice can be 55 protein, functional fragments, derivatives or analogs thereof,
mutated in vitro or in vivo, to create and/or destroy translais operationally associated with a promoter in an expression
tion, initiation, and/or termination sequences, or to create
vector of the invention. Both cDNA and genomic sequences
variations in coding regions and/or form new restriction
can be cloned and expressed under control of such regulatory
endonuclease sites or destroy preexisting ones, to facilitate
sequences. An expression vector also preferably includes a
further in vitro modification. Any technique for mutagenesis 60 replication origin. The necessary transcriptional and translational signals can be provided on a recombinant expression
known in the art can be used, including but not limited to, in
vitro site-directed mutagenesis (Hutchinson et al., 1978, J.
vector.
Biol. Chem. 253: 6551; Zoller and Smith, 1984, DNA 3:479Potential host-vector systems include but are not limited to
mammalian cell systems infected with virus (e.g., vaccinia
488; Oliphant et al., 1986, Gene 44: 177; Hutchinson et al.,
1986, Proc. Natl. Acad. Sci. U.S.A. 83: 710; and others). PCR 65 virus, adenovirus, etc.); insect cell systems infected with
techniques are preferred for site directed mutagenesis (see
virus (e.g., baculovirus); microorganisms such as yeast conHiguchi, 1989, "Using PCR to Engineer DNA", inPCR Techtaining yeast vectors; or bacteria transformed with bacte-
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riophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and
specificities. Depending on the host-vector system utilized,
any one of a number of suitable transcription and translation
elements may be used.
A recombinant protein, may be expressed chromosomally,
after integration of the coding sequence by recombination. In
this regard, any of a number of amplification systems may be
used to achieve high levels of stable gene expression (See
Sambrook et al., 1989, supra).
Numerous techniques are known and are useful according
to the invention for delivering the vectors described herein to
cells, including the use of nucleic acid condensing agents,
electroporation, complexation with asbestos, polybrene,
DEAE cellulose, Dextran, liposomes, cationic liposomes,
lipopolyamines, polyomithine, particle bombardment and
direct microinjection (reviewed by Kucherlapati and Skoultchi, Crit. Rev. Biochern. 16:349-379 (1984); Keown et al.,
Methods Enzymol. 185:527 (1990)).
A vector of the invention may be delivered to a host cell via
a viral or non-viral means of delivery. Preferred delivery
methods of viral origin include viral particle packaging cell
lines as transfection recipients for the vector of the present
invention into which viral packaging signals have been engineered, such as those of adenovirus, herpes viruses and
papovaviruses. Preferred non-viral based gene delivery
means and methods may also be used in the invention and
include direct naked nucleic acid injection, nucleic acid condensing peptides and non-peptides, cationic liposomes and
encapsulation in liposomes.
Methods for constructing and using viral vectors are
known in the art [see, e.g., Miller and Rosman, Bio Techniques
7:980-990 (1992)]. Preferably, the viral vectors are replication defective, that is, they are unable to replicate autonomously in the target cell. In general, the genome of the replication defective viral vectors which are used within the
scope of the present invention lack at least one region which
is necessary for the replication of the virus in the infected cell.
These regions can either be eliminated (in whole or in part),
be rendered non-functional by any technique known to a
person skilled in the art. These techniques include the total
removal, substitution (by other sequences, in particular by the
inserted nucleic acid), partial deletion or addition of one or
more bases to an essential (for replication) region. Such techniques may be performed in vitro (on the isolated DNA) or in
situ, using the techniques of genetic manipulation or by treatment with mutagenic agents. Preferably, the replication
defective virus retains the sequences of its genome which are
necessary for encapsulating the viral particles.
DNA viral vectors include an attenuated or defective DNA
virus, such as but not limited to adenovirus, adeno-associated
virus (AAV), herpes simplex virus (HSY), papillomavirus,
Epstein-Barr virus (EBY), and the like. Defective viruses,
which entirely or almost entirely lack viral genes, are preferred. Defective virus is not infective after introduction into
a cell. Use of defective viral vectors allows for administration
to cells in a specific, localized area, without concern that the
vector can infect other cells. Examples of particular vectors
include, but are not limited to, a defective herpes virus 1
(HSVI) vector [Kaplitt et al., Malec. Cell. Neurosci. 2:320330 (1991)], defective herpes virus vector lacking a glycoprotein L gene [Patent Publication RD 371005 A], or other
defective herpes virus vectors [International Patent Publication No. WO 94/21807, published Sep. 29, 1994; International Patent Publication No. WO 92/05263, publishedApr. 2,
1994]; an attenuated adenovirus vector, such as the vector
described by Stratford-Perricaudet et al. [J. Clin. Invest.

90:626-630 (1992); see also La Salle et al., Science 259:988990 (1993)]; and a defective adeno-associated virus vector
[Samulski et al., J. Viral. 61:3096-3101 (1987); Samulski et
al., J. Viral. 63:3822-3828 (1989); Lebkowski et al., Mal.
Cell. Biol. 8:3988-3996 (1988)].
Adenoviris vectors: in one preferred embodiment, the vector is an adenovirus vector. Adenoviruses are eukaryotic DNA
viruses that can be modified to efficiently deliver a nucleic
acid of the invention to a variety of cell types. Various serotypes of adenovirus exist. Of these serotypes, preference is
given, within the scope of the present invention, to using type
2 or type 5 human adenoviruses (Ad 2 or Ad 5) or adenoviruses of animal origin (see W094/26914). Those adenoviruses of animal origin which can be used within the scope of
the present invention include adenoviruses of canine, bovine,
murine (example: Mavl, Beard 75 (1990) 81), ovine, porcine,
avian, and simian (example: SAY) origin. The adenovirus of
animal origin is a canine adenovirus, more preferably a CAV2
adenovirus (e.g., Manhattan or A26/61 strain (ATCC
VR-800), for example). Adenovirus vectors, adeno-associated virus vectors, parvovirus vectors and herpes simplex
virus vectors are preferred for introducing the nucleic acid
e.g. SCG 1O; Na Channel II; glut-2, synapsin, epo, SCF, shh,
wint, BMPs Ephrins, Pax-6, Emx-2, Mash-1,jagged 1and2,
notch- and 2, ephrin B2 and ephrin B4, Bmi-1, different
homeobox genes HOXB4. The adenovirus vector results in a
shorter term expression (about 2 months) than adeno-associated virus (about 4 months), which in tum is shorter than HSY
vectors. The vectors can be introduced by standard techniques, e.g. infection, transfection, transduction or transformation. Examples of modes of gene transfer include for
example, naked DNA calcium phosphate precipitation,
DEAE dextran, electroporation, protoplast fusion, lipofection, cell microinjection and viral vectors.
Preferably, the replication defective adenoviral vectors of
the invention comprise the ITRs, an encapsidation sequence
and the nucleic acid of interest. Still more preferably, at least
the El region of the adenoviral vector is non-functional. The
deletion in the El region preferably extends from nucleotides
455 to 3329 in the sequence of the Ad5 adenovirus (PvuIIBg!II fragment) or 382 to 3446 (HinfII-Sau3A fragment).
Other regions may also be modified, in particular the E3
region (W095/02697), the E2 region (W094/28938), the E4
region (W094/28 l 52, W094/l 2649 and W095/02697), or in
any of the late genes Ll-L5.
In a preferred embodiment, the adenoviral vector has a
deletion in the El region (Ad 1.0). Examples of El-deleted
adenoviruses are disclosed in EP 185,573, the contents of
which are incorporated herein by reference. In another preferred embodiment, the adenoviral vector has a deletion in the
El and E4 regions (Ad 3.0). Examples of El/E4-deleted
adenoviruses are disclosed in W095/02697 and W096/
22378, the contents of which are incorporated herein by reference. In still another preferred embodiment, the adenoviral
vector has a deletion in the El region into which the E4 region
and the nucleic acid sequence are inserted.
The replication defective recombinant adenoviruses
according to the invention can be prepared by any technique
known to the person skilled in the art (Levrero et al., Gene 101
(1991) 195, EP 185 573; Graham, EMBO J. 3 (1984) 2917).
In particular, they can be prepared by homologous recombination between an adenovirus or modified adenovirus
genome and a plasmid which carries, inter alia, the DNA
sequence of interest. The homologous recombination is
effected following cotransfection of the said adenovirus and
plasmid into an appropriate cell line. The cell line which is
employed should preferably (i) be transformable by the said
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elements, and (ii) contain the sequences which are able to
complement the part of the genome of the replication defective adenovirus, preferably in integrated form in order to
avoid the risks of recombination. Examples of cell lines
which may be used are the human embryonic kidney cell line
293 (Graham et al., J. Gen. Viral. 36 (1977) 59) which contains the left-hand portion of the genome ofanAd5 adenovirus (12%) integrated into its genome, and cell lines which are
able to complement the El and E4 functions, as described in
applications W094/26914 and W095/02697. Recombinant
adenoviruses are recovered and purified using standard
molecular biological techniques, which are well known to
one of ordinary skill in the art.
Adena-associated viruses. In a preferred embodiment, the
vector is an adeno-associated viruses. The adeno-associated
viruses (AAV) are DNA viruses of relatively small size which
can integrate, in a stable and site-specific manner, into the
genome of the cells which they infect. They are able to infect
a wide spectrum of cells without inducing any effects on
cellular growth, morphology or differentiation, and they do
not appear to be involved in human pathologies. The AAV
genome has been cloned, sequenced and characterized. It
encompasses approximately 4700 bases and contains an
inverted terminal repeat (ITR) region of approximately 145
bases at each end, which serves as an origin of replication for
the virus. The remainder of the genome is divided into two
essential regions which carry the encapsidation functions: the
left-hand part of the genome, which contains the rep gene
involved in viral replication and expression of the viral genes;
and the right-hand part of the genome, which contains the cap
gene encoding the capsid proteins of the virus.
The use of vectors derived from theAAVs for transferring
genes in vitro and in vivo has been described (see WO
91/18088; WO 93/09239; U.S. Pat. No. 4,797,368, U.S. Pat.
No. 5,139,941, EP 488 528). These publications describe
various AAV-derived constructs in which the rep and/or cap
genes are deleted and replaced by a gene of interest, and the
use of these constructs for transferring the said gene of interest in vitro (into cultured cells) or in vivo, (directly into an
organism). The replication defective recombinant AAVs
according to the invention can be prepared by cotransfecting
a plasmid containing the nucleic acid sequence of interest
flanked by two AAV inverted terminal repeat (ITR) regions,
and a plasmid carrying theAAV encapsidation genes (rep and
cap genes), into a cell line which is infected with a human
helper virus (for example an adenovirus). The AAV recombinants which are produced are then purified by standard
techniques. The invention also relates, therefore, to anAAVderived recombinant virus whose genome encompasses a
sequence encoding a nucleic acid encoding a tissue maturation factor, (e.g. SCG 10; Na Channel II; glut-2, synapsin,
epo, SCF, shh, wint, BMPs Ephrins, Pax-6, Emx-2, Mash-1,
jagged 1 and 2, notch- and 2, ephrin B2 and ephrin B4, Bmi-1,
different homeobox genes, such as, HOXB4), flanked by the
AAV ITRs; Factor VIII, Factor IX, or mutant genes for ~-glucocerebrosidase, erythropoietin ("EPO"), Q-L-iduronidase,
iduronate sulphatase, N-sulphatase, N-acetyl a-D-glucosaminidase,
a-glucosamine-N-acetyltransferase,
N-acetyl-a-D-glucosaminide-6-sulphatase,
Galactosamine-6 sulphate sulphatase, ~-galactosidase, N-acetylalactosamine-4-sulphatase, acid ceraminidase, acid sphingo~-galactosidase,
myelinase,
galactocerebroside
arylsuphatase A, adenosine deaminase, a-L-fucosidase
growth factors such as the interlenkin family, angiogenesis
stimulating or inhibiting factors such as the nitric oxide synthases (NOSl-3), vascular endothelial growth factors
("VEGF"), Angiostatin 1-7. Other examples of genes useful

for introduction into isolated stem cells include those that
encode Factor VIII, von Willebrand factor, insulin, tissue
plasminogen activator, any of the interleukins, or a growth
factor. Some examples ofinterlenkins include IL-1, -2, -3, -4,
-5, -6, -7, -8, -9, -10, -11, -12, -13, -14, -15, -16, -17, -18, -19,
-20, and -21. Some examples of suitable growth factors
include erythropoietin, thrombopoietin, PDGF, G-CSF, GMCSF, IGF, TGF~, VEGF, and BMP (bone morphogenic protein). The invention also relates to a plasmid encompassing a
sequence encoding a nucleic acid encoding a desired gene
flanked by two ITRs from anAAV. Such a plasmid can be used
as it is for transferring the nucleic acid sequence, with the
plasmid, where appropriate, being incorporated into a liposomal vector (pseudo-virus).
Retrovirus vectors: in another embodiment the gene can be
introduced in a retroviral vector, e.g., as described in Anderson et al., U.S. Pat. No. 5,399,346; Mann et al., 1983, Cell
33:153; Temin et al., U.S. Pat. No. 4,650,764; Temin et al.,
U.S. Pat. No. 4,980,289; Markowitz et al., 1988, J. Viral.
62:1120; Temin et al., U.S. Pat. No. 5,124,263; EP 453242,
EPl 78220; Bernstein et al. Genet. Eng. 7 (1985) 235; McCormick, Bio Technology 3 (1985) 689; International Patent Publication No. WO 95/07358, published Mar. 16, 1995, by Webster, K.A., Kubasiak, L.A., Prentice, H. and Bishopric, N. H.:
Stable germline transmission of a hypoxia-activated molecular gene switch. From the double helix to molecular medicine,
(ed. W. J. Whelan eta!.), Oxford University Press, (2003); and
Kuo et al., 1993, Blood 82:845. The retroviruses are integrating viruses which infect dividing cells. The retrovirus genome
includes two LTRs, an encapsidation sequence and three coding regions (gag, pol and env). In recombinant retroviral
vectors, the gag, pol and env genes are generally deleted, in
whole or in part, and replaced with a heterologous nucleic
acid sequence of interest. These vectors can be constructed
from different types of retrovirus, such as, HIV, MoMuLV
("murine Moloney leukaemia virus" MSV ("murine Moloney sarcoma virus"), HaSV ("Harvey sarcoma virus"); SNV
("spleen necrosis virus"); RSV ("Rous sarcoma virus") and
Friend virus. Defective retroviral vectors are disclosed in
W095/02697.
In general, in order to construct recombinant retroviruses
containing a nucleic acid sequence, a plasmid is constructed
which contains the LTRs, the encapsidation sequence and the
coding sequence. This construct is used to transfect a packaging cell line, which cell line is able to supply in trans the
retroviral functions which are deficient in the plasmid. In
general, the packaging cell lines are thus able to express the
gag, pol and env genes. Such packaging cell lines have been
described in the prior art, in particular the cell line PA317
(U.S. Pat. No. 4,861,719); the PsiCRIP cell line (W090/
02806) and the GP+ envAm-12 cell line (W089/07150). In
addition, the recombinant retroviral vectors can contain
modifications within the LTRs for suppressing transcriptional
activity as well as extensive encapsidation sequences which
may include a part of the gag gene (Bender et al., J. Viral. 61
(1987) 1639). Recombinant retroviral vectors are purified by
standard techniques known to those having ordinary skill in
the art.
Retroviral vectors can be constructed to function as infectious particles or to undergo a single round oftransfection. In
the former case, the virus is modified to retain all of its genes
except for those responsible for oncogenic transformation
properties, and to express the heterologous gene. Non-infectious viral vectors are prepared to destroy the viral packaging
signal, but retain the structural genes required to package the
co-introduced virus engineered to contain the heterologous
gene and the packaging signals. Thus, the viral particles that
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are produced are not capable of producing additional virus.
Targeted gene delivery is described in International Patent
Publication WO 95/28494, published October 1995.
Lentiviral Vectors: lentiviruses include members of the
bovine lentivirus group, equine lentivirus group, feline lentivirus group, ovinecaprine lentivirus group and primate lentivirus group. The development oflentiviral vectors for gene
therapy has been reviewed in Klimatcheva et al., 1999, Frontiers in Bioscience 4: 481-496. The design and use oflentiviral vectors suitable for gene therapy is described, for example,
in U.S. Pat. No. 6,207,455, issued Mar. 27, 2001, and U.S.
Pat. No. 6,165,782, issued Dec. 26, 2000. Examples oflentiviruses include, but are not limited to, HIV-1, HIV-2, HIV1/HIV-2 pseudotype, HIV-lI/SIV, FIV, caprine arthritis
encephalitis virus (CAEV), equine infectious anemia virus
and bovine immunodeficiency virus. HIV-1 is preferred.
Autonomous parvoviruses are small DNA viruses that replicate autonomously in rapidly dividing cells. The genomes of
autonomous parvoviruses do not integrate, at least not at a
detectable level. Autonomous parvovirus genomes are singlestranded DNA molecules about 5 kilo bases (kb) in size. The
genomes are organized such that the NS gene encoding the
nonstructural polypeptides NS 1 and NS2 is located on the left
side of the genome and the VP gene encoding the structural
polypeptides required for capsid formation are on the right
side of the genome. Expression of the nonstructural polypeptides is controlled by a transcription control sequence called
P4 in most parvoviruses, which is located at about map unit
position 4 of the genome (assuming the entire genome is 100
map units and numbering is from left to right). Expression of
the structural polypeptides is controlled by a transcription
control sequence called P38, P39 or P40 in most parvoviruses, which is located at about map unit position 38 to about
40, depending on the autonomous parvovirus. NS 1 serves as
a trans-activator of the latter transcription control sequence.
NS 1 is also essential for virus replication and appears to be
the primary mediator of parvovirus cytotoxicity, particularly
against tumor cells. Autonomous parvovirus genomes also
have inverted repeat sequences (i.e., palindromes) at each end
which contain essential signals for replication and encapsidation of the virus. There have been several studies on the
mechanistics of autonomous parvovirus replication, gene
expression, encapsidation, and cytotoxicity. See, for
example, Sinkovics, pp. 1281-1290, 1989, Anticancer Res.,
Vol 9.
Suitable autonomous parvovirus nucleic acid sequences
include, but are not limited to, LuIII parvovirus (LuIII),
minute virus of mice (MVM; e.g., MVMi and MVMp ), hamster parvovirus (e.g., HI), feline panleukopenia virus, canine
parvovirus, porcine parvovirus, latent rat virus, mink enteritis
virus, human parvovirus (e.g., B 19), bovine parvovirus, and
Aleutian mink disease parvovirus nucleic acid sequences.
LuIII parvovirus is a parvovirus of unknown origin that was
isolated as a contaminant of a substrain of human permanent
cell line Lu106. The LuIII parvovirus exhibits high infectivity.
Non-viral Vectors: alternatively, the vector can be introduced in vivo as nucleic acid free oftransfecting excipients,
or with transfection facilitating agents, e.g., lipofection. For
the past decade, there has been increasing use of liposomes
for encapsulation and transfection of nucleic acids in vitro.
Synthetic cationic lipids designed to limit the difficulties and
dangers encountered with liposome mediated transfection
can be used to prepare liposomes for in vivo transfection of a
gene encoding a marker [Feigner, et. al., Proc. Natl. A cad. Sci.
U.S.A. 84:7413-7417 (1987); see Mackey, et al., Proc. Natl
Acad. Sci. U.S.A. 85:8027-8031 (1988); Ulmer et al., Science

259:1745-1748 (1993)]. The use of cationic lipids may promote encapsulation of negatively charged nucleic acids, and
also promote fusion with negatively charged cell membranes
[Feigner and Ringold, Science 337:387-388 (1989)]. Particularly useful lipid compounds and compositions for transfer of
nucleic acids are described in International Patent Publications W095/18863 and W096/17823, and in U.S. Pat. No.
5,459,127. Other molecules are also useful for facilitating
transfection of a nucleic acid in vivo, such as a cationic
oligopeptide (e.g., International Patent Publication W095/
21931), peptides derived from DNA binding proteins (e.g.,
International Patent Publication W096/25508), or a cationic
polymer (e.g., International Patent Publication W095/
21931).
Naked DNA vectors can be introduced into the desired host
cells by methods known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE
dextran, calcium phosphate precipitation, use of a gene gun,
or use of a DNA vector transporter [see, e.g., Wu etal.,J. Biol.
Chem. 267:963-967 (1992); Wu and Wu, J. Biol. Chem. 263:
14621-14624 (1988); Williams et al., Proc. Natl. Acad. Sci.
USA 88:2726-2730 (1991)]. Receptor-mediated DNA delivery approaches can also be used [Curiel et al., Hum. Gene
Ther. 3: 14 7-154(1992); Wu and Wu, J Biol. Chem. 262:44294432 (1987)]. Methods for formulating and administering
naked DNA to mammalian muscle tissue are disclosed in U.S.
Pat. Nos. 5,580,859 and 5,589,466, the contents of which are
incorporated herein by reference.
Regulatory Regions: expression of, for example, SCG 1O;
Na Channel II; glut-2, synapsin, epo, SCF, shh, wint, BMPs
Ephrins, Pax-6, Emx-2, Mash-1,jagged 1 and2, notch-and2,
ephrin B2 and ephrin B4, Bmi-1, different homeobox genes,
such as, HOXB4, from a vector of the invention may be
controlled by any regulatory region, i.e., promoter/enhancer
element known in the art. Examples also include, Factor VIII,
Factor IX, or mutant genes for ~-glucocerebrosidase, erythropoietin ("EPO"), a-L-iduronidase, iduronate sulphatase,
N-sulphatase, N-acetyl a-D-glucosaminidase, a-glucosamine-N-acety ltransferase,
N-acety l-a-D-glucosaminide-6-sulphatase, Galactosamine-6 sulphate sul~-galactosidase,
N-acetyl-alactosamine-4phatase,
sulphatase, acid ceraminidase, acid sphingomyelinase,
galactocerebroside ~-galactosidase, arylsuphatase A,
adenosine deaminase, a-L-fucosidase growth factors such as
the interleukin family, angiogenesis stimulating or inhibiting
factors such as the nitric oxide synthases (NOS 1-3 ), vascular
endothelial growth factors ("VEGF"), Angiostatin 1-7. Other
examples of genes useful for introduction into isolated stem
cells include those that encode Factor VIII, von Willebrand
factor, insulin, tissue plasminogen activator, any of the interleukins, or a growth factor. Some examples of interleukins
include IL-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, -11, -12, -13, -14,
-15, -16, -17, -18, -19, -20, and-21. Some examples of suitable growth factors include erythropoietin, thrombopoietin,
PDGF, G-CSF, GM-CSF, IGF, TGF~, VEGF, andBMP (bone
morphogenic protein). The regulatory regions may comprise
a promoter region for functional transcription in the tissue of
interest, as well as a region situated in 3' of the gene of
interest, and which specifies a signal for termination oftranscription and a polyadenylation site. All these elements constitute an expression cassette.
Promoters that may be used in the present invention,
include both constitutive promoters and regulated (inducible)
promoters. The promoter may be naturally responsible forthe
expression of the nucleic acid. It may also be from a heterologous source. In particular, it may be promoter sequences
of eukaryotic or viral genes. For example, it may be promoter
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sequences derived from the genome of the cell which it is
desired to infect. Likewise, it may be promoter sequences
derived from the genome of a virus, including the adenovirus
used. In this regard, there may be mentioned, for example, the
promoters of the ElA, MLP, CMV and RSV genes and the
like.
In addition, the promoter may be modified by addition of
activating or regulatory sequences or sequences allowing a
tissue-specific or predominant expression (enolase and GFAP
promoters and the like). Moreover, when the nucleic acid
does not contain promoter sequences, it may be inserted, such
as into the virus genome downstream of such a sequence.
Some promoters useful for practice of this invention are heat
shock protein promoters (hsp ), ubiquitous promoters (e.g.,
HPRT, vimentin, actin, tubulin), intermediate filament promoters (e.g., GFAP, desmin, neurofilaments, keratin), therapeutic gene promoters (e.g., MD R type, CFTR, factor VIII),
tissue-specific promoters (e.g., actin promoter in smooth
muscle cells), promoters which are preferentially activated in
dividing cells, promoters which respond to a stimulus (e.g.,
steroid hormone receptor, retinoic acid receptor), tetracycline-regulated transcriptional modulators, cytomegalovirus
immediate-early, retroviral LTR, metallothionein, SV-40,
ElA, and MLP promoters. Tetracycline-regulated transcriptional modulators and CMV promoters are described in WO
96/01313, U.S. Pat. Nos. 5,168,062 and 5,385,839, the contents of which are incorporated herein by reference.
Thus, the promoters which may be used to control gene
expression include, but are not limited to, GFAP, HSP promoters, the cytomegalovirus (CMV) promoter, the SV40
early promoter region (Benoist and Chambon, 1981, Nature
290:304-310), the promoter contained in the 3' long terminal
repeat of Rous sarcoma virus (Yamamoto, el al., 1980, Cell
22:787-797), the herpes thynidine kinase promoter (Wagner
eta!., 1981, Proc. NatL.Acad. Sci. U.S.A. 78: 1441-1445), the
regulatory sequences of the metallothionein gene (Brinster et
al., 1982, Nature 296:39-42); prokaryotic expression vectors
such as the ~-lactamase promoter (Villa-Kamaroff, et al.,
1978, Proc. NatL. Acad. Sci. U.S.A. 75:3727-3731), or the tac
promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A.
80:21-25); promoter elements from yeast or other fungi such
as the Gal 4 promoter, the ADC (alcohol dehydrogenase)
promoter, PGK (phosphoglycerol kinase) promoter, alkaline
phosphatase promoter.
Various peptides derived from the amino acid sequences of
viral envelope proteins have been used in gene transfer when
co-administered with polylysine DNA complexes (Plank et
al., J. Biol. Chem. 269:12918-12924 (1994)); Trubetskoy et
al., Bioconjugate Chem. 3:323(1992); WO 91/17773; WO
92/19287; and Mack et al., Am. J Med. Sci. 307:138-143
(1994)) suggest that co-condensation of polylysine conjugates with cationic lipids can lead to improvement in gene
transfer efficiency. International Patent Application WO
95/02698 discloses the use of viral components to attempt to
increase the efficiency of cationic lipid gene transfer.
Other methods of delivery of a vector according to the
invention can be accomplished using nucleic acid condensing
peptides. Nucleic acid condensing peptides, which are particularly useful for condensing the vector and delivering the
vector to a cell, are described in WO 96/41606. Functional
groups may be bound to peptides useful for delivery of a
vector according to the invention, as described in WO
96/41606. These functional groups may include a ligand that
targets a specific cell-type such as a monoclonal antibody,
insulin, transferrin, asialoglycoprotein, or a sugar. The ligand
thus may target cells in a non-specific manner or in a specific
manner that is restricted with respect to cell type. Nucleic acid

condensing agents useful in the invention include spermine,
spermine derivatives, histones, cationic peptides, cationic
non-peptides such as polyethyleneimine (PEI) and polylysine. Spermine derivatives refers to analogues and derivatives of spermine and include compounds as set forth in
International Patent Application. WO 93/18759 (published
Sep. 30, 1993). Delivery vehicles for delivery of DNA constructs to cells are known in the art and include DNA/polycation complexes which are specific for a cell surface receptor, as described in, for example, Wu and Wu, J. Biol. Chem.
263:14621 (1988); Wilson et al., J. Biol. Chem. 267:963
(1992); and U.S. Pat. No. 5,166,320).
In a preferred embodiment, the delivery vehicle comprises
a functional group. The functional groups also may comprise
a lipid, such as palmitoyl, oleyl, or stearoyl; a neutral hydrophilic polymer such as polyethylene glycol (PEG), or polyvinylpyrrolidine (PVP); a fusogenic peptide such as the HA
peptide of influenza virus; or a recombinase or an integrase.
The functional group also may comprise an intracellular trafticking protein such as a nuclear localisation sequence (NLS)
and endosome escape signal or a signal directing a protein
directly to the cytoplasm.
In a preferred embodiment, the stem cells are transformed
with nucleic acids which encode for desired tissue specific
targeting markers, such as for example, endothelial markers-VEGFR, Tie-1, EC-1, EnPo 1.
In another preferred embodiment, the invention provides
methods for the targeting and tracking of stem cells to specific
locations within an animal's body. The methods used herein
are also useful in the therapeutic applications of repairing or
colonizing specifically targeted areas within an animal, with
stem cells, which then differentiate into mature cells of the
specific cell type of the targeted area.
In a preferred embodiment, the method of the invention
optionally comprises vectors expressing antibodies specific
to antigens in a desired target area. A second antibody can be
used for the in vivo tracking of the stem cell from any area in
the animal's body to the desired target area.
In accordance with the invention, stem cells from a patient
are harvested, sorted, purified and identified. The stem cells
are then transduced with an expression vector comprising
nucleic acid sequence encoding an antibody which will target
the stem cell to the targeted location. In accordance with the
invention, this procedure can be used for different antigen
specificities of stem cells. Different isotypes of the arming
antibody (e.g. IgGl, etc.) can be detected by utilizing secondary antibodies specific for the isotype. The secondary antibody can come from different sources, e.g. rat, sheep, goat
etc; the important property being that it is targeted against the
species of origin of the primary antibody. Also, secondary
antibodies conjugated with different fluorochromes can be
used, e.g. PE, FITC, APC, etc.
Alternatively, antibodies can be conjugated to a stem cells
surface using linkers, chemical conjugates and the like.
In a preferred embodiment, exogenous DNA segments, for
example, SCG 1O; Na Channel II; glut-2, synapsin, epo, SCF,
shh, wint, BMPs Ephrins, Pax-6, Emx-2, Mash-1, jagged 1
and 2, notch- and 2, ephrin B2 and ephrin B4, Bmi-1, Factor
VIII, Factor IX, or mutant genes for ~-glucocerebrosidase,
erythropoietin ("EPO"), a-L-iduronidase, iduronate sulphatase, N-sulphatase, N-acetyl a-D-glucosaminidase,
a-glucosamine-N-acety ltransferase,
N-acety1-a-D-glucosaminide-6-sulphatase, Galactosamine-6 sulphate sul~-galactosidase,
N-acetyl-alactosamine-4-sulphatase,
phatase, acid ceraminidase, acid sphingomyelinase,
galactocerebroside ~-galactosidase, arylsuphatase A,
adenosine deaminase, a-L-fucosidase growth factors such as
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the interleukin family, angiogenesis stimulating or inhibiting
factors such as the nitric oxide synthases (NOSl-3), vascular
endothelial growth factors ("VEGF"), Angiostatin 1-7. Other
examples of genes useful for introduction into isolated stem
cells include those that encode Factor VIII, von Willebrand
factor, insulin, tissue plasminogen activator, any of the interleukins, or a growth factor. Some examples of interleukins
include IL-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, -11, -12, -13, -14,
-15, -16, -17, -18, -19, -20, and-21. Some examples of suitable growth factors include erythropoietin, thrombopoietin,
PDGF, G-CSF, GM-CSF, IGF, TGF~, VEGF, andBMP (bone
morphogenic protein), different homeobox genes HOXB4,
typically include an expression control DNA sequence operably linked to a tissue-specific promoter. Examples of tissue
specific promoters are shown in Table 1. Below is a list of
promoters additional to the tissue specific promoters listed
above, cellular promoters/enhancers and inducible promoters/enhancers that could be; used in combination with the
nucleic acid encoding a gene of interest in an expression
construct. Additionally, any promoter/enhancer combination
(as per the Eukaryotic Promoter Data Base EPDB) could also
be used to drive expression of the gene. Enkaryotic cells can
support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided,
either as part of the delivery complex or as an additional
genetic expression construct.
TABLE 1

TABLE2
Inducer

MTII

Phorbol Ester (TPA)
Heavy metals
Glucocorticoids

MMTV (mouse mammary tumor
virus)
13-Interferon
10 Adenovirus 5 E2
c-jun
Collagenase
Stromelysin
SV40
Murine MX Gene
15 GRP78 Gene
a-2-Macroglobulin
Vimentin
MHC Class I Gene H-2kB
HSP70
Proliferin
Tumor Necrosis Factor
20
Thyroid Stimulating Hormone
Gene
Insulin E Box

25

30

PROMOTER AND/OR ENHANCER
Irnmunoglobulin Heavy Chain
Irnmunoglobulin Light Chain
T-Cell Receptor
HLA DQa and DQl3
13.-Interferon
Interleukin-2
Interleukin-2 Receptor
MHC Class II HLA-DRa
13-Actin
Muscle Creatine Kinase
Prealbumin (Transthyretin)
Elastase I
Metallothionein
Collagenase
Albumin Gene
a-Fetoprotein
i:-Globin
13-Globin
e-fos
c-HA-ras
Insulin
Neural Cell Adhesion Molecule (NCAM)
al-Antitrypsin
H2B (TH2B) Histone
Mouse or Type I Collagen
Glucose-Regulated Proteins (GRP94 and GRP78)
Rat Growth Hormone
Human SerumAmyloidA (SAA)
Troponin I (TN I)
Platelet-Derived Growth Factor
Duchenne Muscular Dystrophy
SV40
Polyoma
Retroviruses
Papilloma Virus
Hepatitis B Virus
Hwnan Immllilodeficiency Virus
Cytomegalovirus
Gibbon Ape Leukemia Virus
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poly(rl)X
poly(rc)
El A
Phorbol Ester (TPA), H2 0 2
Phorbol Ester (TPA)
Phorbol Ester (TPA), IL-1
Phorbol Ester (TPA)
Interferon, Newcastle Disease Virus
A23187
IL-6
Serum
Interferon
ElA, SV40 Large T Antigen
Phorbol Ester-TPA
FMA
a-Thyroid Hormone
Glucose

The identity of tissue-specific promoters or elements, as
well as assays to characterize their activity, is well known to
those of skill in the art. Examples of such regions include the
human LIMK2 gene (Nomoto et al. Gene, 236(2):259-271,
1999), the somatostatin receptor 2 gene (Kraus et al., FEES
Lett., 428(3):165-70, 1998),murineepididymalretinoicacidbinding gene (Lareyre et al., J. Bio. Chem., 274(12):8282-90,
1999), human CD4 (Zhao-Emonet et al., Biochim. Biophys.
Acta, 1442(2-3):109-19, 1998), mouse alpha 2 (XI) collagen
(Tsumaki, et al., 1998), DIA dopamine receptor gene (Lee, et
al., DNA Cell Biol., 16(11):1267-75, 1997), insulin-like
growth factor II (Wu et al., Biochem. Biophys. Res. Commun.,
233(1):221-6, 1997; Wu et al., J. Med. Viral., 52:83-85.
1997), human platelet endothelial cell adhesion molecule- I
(Almendro et al., J Immunol., 157(12):5411-21, 1996).
Preferably, the expression control sequences will be
enkaryotic promoter systems in vectors capable of transforming or transfecting stem host cells, but control sequences for
prokaryotic hosts may also be used. Vectors can be constructed which also comprise a detectable/selectable marker
gene. In preferred embodiments these marker genes are fluorescent proteins such as green fluorescent protein (GFP),
cyan- (CFP), yellow- (YFG), blue- (BFP), red- (RFP) fluorescent proteins; enhanced green fluorescent protein (EGFP),
EYFP, EBFP, Nile Red, dsRed, mutated, modified, or
enhanced forms thereof, and the like.
As used herein, the "green-fluorescence protein" is a gene
construct which in transfected or infected cells, respectively,
shines green under ultraviolet light and thus enables the
detection of a cell transfected or infected, respectively, with
GFP in a simple mamier. Uses of green fluorescent protein for
the study of gene expression and protein localization are well
known. The compact structure makes GFP very stable under
diverse and/or harsh conditions such as protease treatment,
making GFP an extremely useful reporter in general.
New versions of green fluorescent protein have been developed, such as a "humanized" GFP DNA, the protein product
of which has increased synthesis in mammalian cells. One
such humanized protein is "enhanced green fluorescent protein" (EGFP). Other mutations to green fluorescent protein
have resulted in blue-, cyan- and yellow-green light emitting
vers10ns.
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Endogenously fluorescent proteins have been isolated and
cloned from a number of marine species including the sea
pansies Renilla reniformris, R. kollikeri and R. mullerei and
from the sea pens Ptilosarcus, Stylatula and Acanthoptilum,
as well as from the Pacific Northwest jellyfish, Aequorea
victoria; Szent-Gyorgyi et al. (SPIE conference 1999), D. C.
Prasher et al., Gene, 111 :229-233 (1992) and several species
of coral (Matz et al. Nature Biotechnology, 17 969-973
(1999). These proteins are capable of forming a highly fluorescent, intrinsic chromophore through the cyclization and
oxidation of internal amino acids within the protein that can
be spectrally resolved from weakly fluorescent amino acids
such as tryptophan and tyrosine.
In another preferred embodiment, stem cells comprise vectors expressing desired chemokines. Chemokines and cytokines play a powerful role in the development of an immune
response. The role of chemokines in leukocyte trafficking is
reviewed by Baggiolini (1998) Nature 392:565-8, in which it
is suggested that migration responses in the complicated trafficking oflymphocytes of different types and degrees of activation will be mediated by chemokines. The use of small
molecules to block chemokines is reviewed by Baggiolini and
Moser (1997) J. Exp. Med. 186:1189-1191.
The role of various specific chemokines in lymphocyte
homing has been previously described. For example, Campbell et al. (1998) Science, showed that SDF-1 (also called
PBSF), 6-C-kine (also called Exodus-2), and MIP-3~ (also
called ELC or Exodus-3) induced adhesion of most circulating lymphocytes, including most CD4+ T cells; and MIP-3a
(also called LARC or Exodus-I) triggered adhesion of
memory, but not naive, CD4+Tcells. Tangemannetal. (1998)
J. Immunol. 161 :6330-7 disclose the role of secondary lymphoid-tissue chemokine (SLC), a high endothelial venule
(HEV)-associated chemokine, with the homing of lymphocytes to secondary lymphoid organs. Campbell et al. (1998)J.
Cell Biol 141(4):1053-9 describe the receptor for SLC as
CCR7, and that its ligand, SLC, can trigger rapid integrindependent arrest of lymphocytes rolling under physiological
shear.
Any of the methods previously described for the insertion
of DNA fragments into a cloning vector may be used to
construct expression vectors containing a gene consisting of
appropriate transcriptional/translational control signals and
the protein coding sequences. These methods may include in
vitro recombinant DNA and synthetic techniques and in vivo
recombination (genetic recombination). Expression of proteins, may be controlled by any promoter/enhancer element
known in the art, but these regulatory elements must be functional in the host selected for expression.
Expression vectors containing a nucleic acid encoding a
desired polypeptide, can be detected or identified by four
general approaches: (a) PCR amplification of the desired
plasmid DNA or specific mRNA, (b) nucleic acid hybridization, (c) presence or absence of selection marker gene functions, and (d) expression of inserted sequences. In the first
approach, the nucleic acids can be amplified by PCR to provide for detection of the amplified product. In the second
approach, the presence of a foreign gene inserted in an expression vector can be detected by nucleic acid hybridization
using probes comprising sequences that are homologous to an
inserted marker gene. In the third approach, the recombinant
vector/host system can be identified and selected based upon
the presence or absence of certain "selection marker" gene
functions (e.g., ~-galactosidase activity, thymidine kinase
activity, resistance to antibiotics, transformation phenotype,
occlusion body formation in baculovirus, etc.) caused by the
insertion of foreign genes in the vector. In another example, if

the nucleic acid a desired polypeptide is inserted within the
"selection marker" gene sequence of the vector, recombinants
containing the protein insert can be identified by the absence
of the gene function.
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Stem Cell Maturity and Cell Differentiation
In accordance with the invention, it is desirable to determine cell maturity and differentiation. Several different ways,
to assess maturity and cell differentiation, are available. For
example, one such method is by measuring cell phenotypes.
The phenotypic changes can be evaluated by flow cytometry
after immunofluorescent staining using monoclonal antibodies that will bind membrane proteins characteristic of various
cell types.
Introducing Cells into the Biocompatible Material
If desired, cells can be introduced into a porous biocompatible material. Generally, cells are introduced into the material of the present invention in vitro, although in vivo seeding
approaches are employed in some circumstances. It is important that adequate growth (or storage) medium be provided to
ensure cell viability. If the composition is to be implanted for
use in vivo after in vitro seeding, sufficient growth medium
must be supplied to ensure viability throughout, and for a
short time following, the implant proceeding. Once the composition has been implanted, the porous nature of the material
allows the cells' nutritional requirements to be met by the
circulating fluids of the host.
Dulbecco's minimal essential medium to be particularly
useful in the practice of the present invention. Other solutions
that may be employed include, but are not limited to, phosphate-buffered saline; carbonate-, HEPES-, or TRIS-buffered
solutions. In some cases, additional growth-stimulating components, such as serum, growth factors, amino acid nutrients,
sugars, and salts, may be added to the aqueous solution
employed in the present invention.
In the embodiment, wherein the biocompatible material is
porous, cells are able to readily migrate into it. Any available
method may be employed to introduce the cells to the material. For example, cells may be introduced by means such as
culturing, pressure, vacuum, or osmosis. Alternatively (or
additionally), cells may be layered on the material, or the
material may be dipped into a cell suspension and allowed to
remain there under conditions and for a time sufficient for
cells to impregnate the material. Generally, it is desirable to
avoid excessive manual manipulation of the cells in order to
minimize cell death during the impregnation procedure. Cells
may also be introduced into the material in vivo simply by
placing the material in the body adjacent a source of desired
cells. In some cases, it may be desirable to enhance such in
vivo cell impregnation by including within the material an
appropriate chemotactic factor, associative factor (i.e., a factor to which cells bind), or factor that induces differentiation
of cells into the desired cell type.
As those of ordinary skill will readily appreciate, the number of cells to be introduced into the inventive material will
vary based on the intended application of the seeded material
and on the type of cell used. Where dividing autologous cells
are being introduced by use of 5,000-1,000,000 cells per cm3
are expected to result in cellular proliferation and extracellular matrix formation within the material. Where non-dividing
cells are employed, larger numbers of cells will generally be
required. In those cases where seeding is accomplished by
host cell migration into the material in vivo, exposure of the
material to fluids containing cells (e.g., bone-forming cells),
or to tissue (e.g., bone) itself is effective to seed the material
with cells without the need for inoculation with a specified
number of cells.
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Applications
Mannnalian bone tissue has a remarkable ability to regenerate and thereby repair injuries and other defects. For
example, bone growth is generally sufficient to bring about
full recovery from most simple and hairline fractures. Unfortunately, however, there are many injuries, defects or conditions where bone growth is inadequate to achieve an acceptable outcome. For example bone regeneration generally does
not occur throughout large voids or spaces. Therefore, fractures cannot heal unless the pieces are in close proximity. If a
significant amount of bone tissue was lost as a result of the
injury, the healing process may be incomplete, resulting in
undesirable cosmetic and/or mechanical outcomes. This is
often the case with non-union fractures or with bone injuries
resulting from massive trauma. Tissue growth is also generally inadequate in voids and segmental gaps in bone caused,
for example, by surgical removal of tumors or cysts. In other
instances, it may be desirable to stimulate bone growth where
bone is not normally found, i.e., ectopically. Spine fusion to
relieve lower back pain where two or more vertebrae are
induced to fuse is one example of desirable ectopic bone
formation. Currently, such gaps or segmental defects require
bone grafts for successful repair or gap filling. The development of effective bone graft substitutes would eliminate the
need to harvest bone from a second surgical site for a graft
procedure, thereby significantly reducing the discomfort
experienced by the patient and risk of donor site healing
complications.
The combination of stem cells and the biocompatible material, referred to herein as "the composition" or "biocomposition", can be usefully employed in any of a variety of in vivo
and in vitro systems. For example, the material may be used
in bone tissue or repair applications or augmentation plastic
therapy in vivo. Alternatively or additionally, the material
may be employed as a stem cell adhesion membrane or
matrix. The material may also be utilized in artificial organ
construction or repair.
In vitro, the material may be used as a three dimensional
cell culture matrix, and as a model for analyzing osteoclast,
osteoblast, chondrocyte, and/or macrophage cultures, progenitor cell differentiation, and/or reossification and calcium
phosphate resorption. The material is particularly useful for
tissue formation and/or degradation studies, for example
employing cells such as progenitor cells, stem cells, osteocytes, osteoclasts, osteoblasts, chondrocytes, macrophages,
myoblasts, and fibroblasts. Certain preferred applications are
discussed in more detail below, but the discussion is intended
only for purposes of exemplification and is not intended to be
limiting.
Bone Production and Healing: In preferred embodiments
of the present invention, the biocompatible material is cultured with bone-forming cells or precursors thereof. Preferably, the biocompatible material is formulated, and the cell
population is selected, so that the biocompatible material
becomes ossified within a period of about 4-12 weeks.
In particularly preferred embodiments of the invention, the
culturing is accomplished by placing the biocompatible material in contact with a source of the host's own bone-producing
cells. Such cells are found in bone tissue or in bone-associated
blood or fluids, including exogenous fluids that have been in
contact with bone (including cancerous bone), bone materials, or bone regions such as the periosteum or the marrow.
In a preferred embodiment, the stem cells are autologous
stem cells. Bone forming cells harvested from the host are
cultured in vitro so that the composition is implanted in the
host with the stem cells attached to the surface of the biocompatible material. Furthermore, culturing of non-autologous
stem cells is also within the scope of the invention. Such
non-autologous cells can be obtained from any of a variety of
sources, including but not limited to primary sources, cell
lines, and cell banks.

Bone formation in and around the composition can be
enhanced by the incorporation of trophic factors and/or bonegrowth inducing factors into, or onto, the biocompatible
material device.
Osseous Augmentation: The compositions of the present
invention are useful for the enhancement or alteration of the
shape of bony structures (e.g., a chin). For such applications,
the composition may be supplied in a desired shape and
applied to a bony surface. The compositions employed in
augmentation applications maybe seeded, if desired through
application of cells or cell lines to the biocompatible material,
although some preferred embodiments involve host cell seeding. The term "host cell seeding" encompasses any method by
which cells of the host are introduced into the biocompatible
material. For example, the term encompasses migration of
host cells into a device implanted in vivo, as well as assisted
migration accomplished by placing bone blood or fragments
of the periosteum on or in contact with the device (in vivo or
in vitro), among other things.
Cartilage Production and Healing: Damage to cartilage can
result in serious physical deformations. Currently, the most
common treatment for loss of cartilage is replacement with a
prosthetic material, but many difficulties have been encountered with this approach. The compositions of the present
invention offer an attractive alternative in which the biocompatible material acts as a formable scaffold into and within
which tissue can grow.
The biocompatible material of the present invention can be
porous so it can be seeded with stem cells as well as attachment of stem cells on the surface of the biocompatible material. Preferably, the cells are cultured as described in detail in
the examples which follow, by placing the device in contact
with a source of the host's own cartilage-forming cells (e.g.,
chondrocytes) or precursors thereto. Such cells are found in
cartilage-associated blood or fluids, including exogenous fluids that have been in contact with cartilage or cartilagenous
materials. Thus, fluids that have been in contact with the
perichondrium, cartilage, or marrow typically contain such
cells.
In many cases, e.g., a biocomposition designed for augmentation of a damaged ear, seeding can be accomplished by
placing the biocomposition in contact with the breached
region of the perichondrium. In other cases, it will be useful to
surgically prepare a seating for the biocomposition within
existing cartilagenous tissue by removing a portion of the
cartilage at the implant site.
In some embodiments of the present invention, additional
steps may be taken to augment chondrogenesis associated
with the cells and biocompatible material. For example, cartilage-forming cells harvested from the patient may be introduced into the device in addition (or as an alternative to) cells
that impregnate it after implantation in vivo. Alternatively or
additionally, trophic factors or cartilage growth-inducing factors may be incorporated into or onto the device.
It should be clear that autologous cells are not required for
the biocomposition employed in cartilage-forming applications; non-autologous cells are also within the scope of the
invention so long as the cells are selected and the biocompatible material is formulated so that a desired amount of cartilage regeneration occurs prior to host rejection of the cartilage-forming cells. Thus, cells or tissues obtained from
primary sources, cells lines, or cell banks are useful in the
practice of this embodiment of the present invention.
Ectopic Bone or Cartilage Production: The biocompositions of the present invention can be used to produce bone or
cartilage formation at a site at which bone or cartilage does
not normally occur. Introduction of a biocomposition into
which bone- or cartilage-producing cells have been seeded
into an in vivo implant site will result in bone or cartilage
formation at that site. In preferred embodiments, the biocomposition contains growth and/or trophic factors in addition to
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the cells, so that maintenance of the ectopically-formed bone
or cartilage can be prolonged. Once it has been produced,
such ectopic tissue may either be left in place or may be
surgically removed, depending on its intended use. Alternatively or additionally, trophic or growth factors external to the
implant may be provided, e.g., through the use of encapsulated cells, polymer implants, or other method of factor delivery (see, for example, Aebischer et al., U.S. Pat. No. 4,892,
538; Sefton, U.S. Pat. No. 4,353,888 and Winn et al.
Experimental Neurology 140:126 (1996)).
ResearchApplications: The biocompositions of the present
invention, due to its ease of preparation, mild formation conditions, sparing solubility in most aqueous systems, and tractability, provides an attractive three-dimensional growth
matrix for use in research and production tissue culture applications. Furthermore, the material is useful for tissue formati on and/or degradation studies (e.g., of bone or cartilage).
Preferably, the material employed in such studies comprises
cells attached to the surface, and/or is porous to allow seeding
with cells. Examples of cells include (but not limited to)
progenitor cells, stem cells, osteocytes, osteoclasts, osteoblasts, chondrocytes, macrophages, myoblasts, and fibroblasts.
Diagnostics: The biocompositions of the present invention
may be employed in diagnostics that detect various health or
disease states. For example, the biocomposition can be used
in qualitative or quantitative assays to determine the bone- or
cartilage-forming potential of cells taken from a patient to be
diagnosed. The biocomposition can also be used in diagnostics to assay vascularization and hard tissue degradation. Various soft tissue diagnostics are also made possible with the
biocompositions.
The following examples are offered by way of illustration,
not by way oflimitation. While specific examples have been
provided, the above description is illustrative and not restrictive. Any one or more of the features of the previously
described embodiments can be combined in any marmer with
one or more features of any other embodiments in the present
invention. Furthermore, many variations of the invention will
become apparent to those skilled in the art upon review of the
specification.
All publications and patent documents cited in this application are incorporated by reference in pertinent part for all
purposes to the same extent as if each individual publication
or patent document were so individually denoted. By their
citation of various references in this document, Applicants do
not admit any particular reference is "prior art" to their inventi on.

flask into waste container and 5 ml of trypsin (0.25% Gibco/
Invitrogen) was added to flask. The flask was incubated for 90
seconds@ 37° C. and 10 ml of plain DMEM was added ip
deactivate trypsin. Contents of flask (cell suspension) was
decanted into a 50 ml conical tube. The cell suspension was
centrifuged for 5 min@ 300 RPM, supernatant was removed
from 50 ml conical tube. The cell suspension was then plated
into 6 well tissue culture plates at approximately 25,000 per
well.
The cells on the material surface were visualized using
staining with green fluorescent dye. For the transfection of
green fluorescent protein vector, a reposomal-transfection
method was used. For staining with the dye, cells were incubated in media containing 30 µM of the ~e for few hours.
The NT2/Dl cells were seeded (5x10 cells per 150 mm
petri dish) in Dulbecco' s modified Eagle's medium with F-12
(DMEM/F-12; Invitrogen) supplemented with 10% heat
inactivated fetal bovine serum (Novacell), 1% antibiotic-antimycotic (Invitrogen), 4 mM glutamine (Invitrogen) and
maintained in a humidified atmosphere of 5% C0 2 /95% air at
3 7° C. ). The cells were passed twice a week by short exposure
to trypsin/EDTA (Invitrogen). For the experiments, lxlO
NT-2/Dl cells were plated on the synthetic bone in a 6 well
tissue culture plate. EGFP expression or green fluorescent
dye in the cells was detected as green fluorescence signals
under a microscope (Leica, model DMRB).
FIG. 1 shows a scarmed image of mesenchymal stem cells
isolated from adult human bone marrow stained with green
fluorescent dye. The green stained cells 120 can be seen to be
in various size areas bound to the darker synthetic bone 110.
The stained cells 120 appear as light regions 120 in the black
and white figure provided.
Since mesenchymal stem cells are committed to produces
bone and other connecting tissue, it is expected to accelerate
healing process of the bone. However, mesenchymal stem
cells are well known to not bind to most materials, including
de-calcified real bone. Thus, the binding of the cells to the
synthetic bone is itself highly significant. Since the bone
material is bio-compatible, the mesenchymal stem cells will
provide a bridge between the endogenous tissue (bone) and
the synthetic bone.
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EXAMPLES
It should be understood that the Examples described below
are provided for illustrative purposes only and do not in any
way define the scope of the invention.

50

Example 1
Stem Cell Adhesion
Simulated bone made of ceria stabilized zirconia was sterilized via dry cycle autoclave and co-cultured with human
progenitor cells or stem cells in DMEM culture media supplemented with 10% bovine fetal serum for 24 hours. The porous
prototype article was made by near-net shape plasma
nanomanufacturing as described above. The human progenitor cells were cultured in a T75 tissue culture flask using
media consisting of DMEM Gibco (Dulbeccos modified
eagles medium). 10% FBS Novacell (Fetal Bovine Serum).
1% Antibiotic/Antimycotic Gibco till they reach approximately 80% confluency. The medium was decanted from

Example 2
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A porous, near-net shape ceria-stabilized zirconia article
for a specific biomedical application was formed using a
plasma spraying process. A scanned image of the article is
shown in FIG. 2. The cylindrical shape and size were specifically designed for this application, simulating the shape and
size of a bone segment. Thus, the plasma processing is an
effective method for consolidation of nanomaterials to large
near-net-shape components with the desired shape and size.
The experimental parameters for developing of the Ceriastabilized Zirconia component were selected as following:
current: 850 Amps, primary Gas: Ar: 82 SCFH, secondary
gas: He: 40 SCFH, powder feeding rate: 2.5 RPM, carrier gas:
13 SCFH.
It was found that when there is an increase of the ceria
concentration in the Ceria stabilized Zirconia system, the
amount of the tetragonal phase increases and the grain size of
Zirconia decreases. An 18% Ceria content powder was used
for plasma developing of the desired component.
The developed material was characterized with modern
equipment. Using X-Ray Diffraction (XRD), it was clearthat
there is some amount of monoclinic phase in the Ceria stabilized Zirconia powder. Previously, it had been found that the
Zirconia femoral heads undergo surface degradation and
reduction of mechanical properties as result of the tetragonal
(t) to monoclinic (in) phase transformation. Thus the dilata-
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tion and shear strains associated with the t---;.transformation
can be the reason for microcracking and degradation of the
material. However, in this experiment, after the plasma processing the only phase detected was a non-equilibrium tetragonal t' phase. As a result, the existence of this metastable
tetragonal phase in the plasma-sprayed Ce0 2 stabilized Zr0 2
may be beneficial to the biological tissue growth in this
experiment.
From the X-Ray Photoelectron Spectroscopy (XPS) characterization of the as-sprayed near-net shape part it was found
that the Ce+4 concentrations on the surface of the component
are higher than in the powder before spraying. The c+4 oxidation state transformation can be attributed to some degree
of oxidation during part manufacturing. In this case, however,
the Ce+ 3 states are still present, which can be a key promoter
for the bio-cell compatibility. The developed advanced scaffolds show comparable bioactivity for the first time and
improved bonding strength to the biological tissues-possibly due to the ce+ 3 states.
Therefore, this preferred embodiment of the invention
combines the benefits of the plasma nano-manufacturing to
near-net-shape components with various shapes. In addition,
the benefits of both Cerium Oxide and its unique oxidation
state transformations and the non-equilibrium tetragonal
phase formation as result of the plasma processing are incorporated. All K combined, these benefits lead to better properties and enhanced bio-medical functions of the material.

particles having Ce 3 + molecules, the cerium nanoparticles having an average particle size ofless than 20 nm;
and
wherein the average particle size of less than 20 nm is
effective to provide an increased amount of the reduced
ceria nanoparticles on the surfaces of said biocompatible
material relative to larger cerium nanoparticles.
2. The biocomposite of claim 1, wherein said biocompatible material is a porous material.
3. The biocomposite of claim 1, wherein said biocompatible material comprises ceria stabilized zirconia.
4. The biocomposite of claim 1, wherein the surface of the
biocompatible material comprises about 10% to about 90%
Ce 3 + molecules versus Ce4 + molecules.
5. The biocomposite of claim 1, wherein the surface of the
biocompatible material comprises at least 10% Ce3 + molecules versus Ce4 + molecules.
6. The biocomposite of claim 1, wherein the surface of the
biocompatible material comprises about 20% Ce3 +molecules
versus Ce4 + molecules.
7. The biocomposite of claim 1, wherein the surface of the
biocompatible material comprises about 30% Ce3 +molecules
versus Ce4 + molecules.
8. The biocomposite of claim 1, wherein the surface of the
biocompatible material comprises about 10% to about 99%
Ce4 + molecules versus Ce3 + molecules.
9. The biocomposite of claim 1, wherein the stem cells are
derived from autologous bone marrow.
10. The biocomposite of claim 1 wherein the stem cells are
selected from Lin-, Sca-1 +,or c-kit+.
11. The biocomposite of claim 1, wherein said biocompatible material comprises a porous, near-net shape macroscopic
article formed using a plasma spraying process.
12. The biocomposite of claim 1, wherein said biocompatible material further comprises a coating of cell-adhesion
molecules.
13. The biocomposite of claim 1, wherein said plurality of
living human progenitor or living stem cells have been contacted with a gene encoding a bone morphogenic protein.
14. The biocomposite of claim 1, wherein the cerium nanoparticles are in a non-agglomerated state.
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Other Embodiments
It is to be understood that while the invention has been
described in conjunction with the detailed description
thereof, the foregoing description is intended to illustrate and
not limit the scope of the invention.
All references cited herein, are incorporated herein by reference.
We claim:
1. A biocomposite, comprising:
a biocompatible solid material, and
a plurality of living human progenitor or living stem cells
attached to a surface of said biocompatible material;
wherein the biocompatible material comprises cerium
nanoparticles on surfaces of said biocompatible material;
wherein the cerium nanoparticles comprise ceria nanoparticles having Ce4 + molecules and reduced ceria nano-
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